

NATIONAL QUALITY FORUM

TO: NQF Members

FR: NQF Staff

RE: Voting for *National Voluntary Consensus Standards for Patient Safety Measures, Second Report: A Consensus Report*

DA: April 6, 2011

Background

NQF has endorsed more than 100 performance measures that are directly related to patient safety. These endorsed measures are relevant in several different environments of care and are applicable to a variety of healthcare professionals. As with the preceding measures, the measures presented in this report address broad issues within patient safety, including capacity, productivity, and improving patient outcomes.

This Patient Safety Measures project will present two reports – the first focuses on five healthcare-associated infections (HAI) and this report on medication safety, querying and counseling on side-effects, colonoscopy processing, and radiation dosing. The first report has been delayed to allow measure developers sufficient time to address harmonization issues related to two surgical site infection measures. Following their work towards harmonization, the HAI measures will be presented to NQF membership for vote.

Ultimately, the standards presented in both reports will provide stakeholders with an improved picture of patient safety within a range of healthcare settings in the United States. Please note that none of the medication safety or querying and counseling measures were recommended for endorsement. Please refer to the Candidate Standards Not Recommended for Endorsement section of the report for more information on these measures.

Comments and Revised Draft Report

The comment period for the draft report, *National Voluntary Consensus Standards for Patient Safety Measures, Second Report: A Consensus Report*, concluded on February 9, 2011. NQF received 43 comments from 11 organizations on the report. The distribution of comments by Member Council follows:

Consumers - 1	Health Professionals-3
Purchasers-1	Public Health/Community-0
Health Plans-1	QMRI-0
Providers-2	Supplier and Industry-0
Non-members-3	

The Committee's recommendations are presented by measure topic area – colonoscopy processing measures and radiation dosing measures. Several comments related to the three colonoscopy processing measures addressed concerns across the group; therefore, those comments are presented jointly. Comments were submitted for the two radiation dosing measures collectively and individually. All measure-specific comments were forwarded to the measure developers, who were invited to respond. A table of detailed comments submitted during the review period, with responses and actions taken by the Steering Committee, is posted on the NQF voting webpage. Revisions to the draft report and accompanying measure specifications table (Appendix A) have been made using the track changes functionality.

**NQF REVIEW DRAFT: DO NOT CITE OR QUOTE
NQF MEMBER VOTES DUE TO NQF BY MAY 5, 2011 6:00 PM ET**

NATIONAL QUALITY FORUM

Comments and Their Disposition

General comments

Several comments expressed concern about the readiness of the colonoscopy measures for public reporting and as national quality standards. Others questioned the use of dose indices as a proxy for assessing radiation exposure and adsorption. Those comments are summarized below by measure topic area. Measure-specific comments typically addressed issues of feasibility and usability. All of these issues were discussed by the Committee prior to making its recommendations and following the comment period.

Use of colonoscopy processing measures as national performance standards (PSM-014-10, PSM-015-10, and PSM-016-10)

Measures # PSM-014-10, PSM-015-10, and PSM-016-10 assess colonoscopy processing related to personnel instruction, currency, and competency respectively. A number of commenters questioned whether these measures would be more appropriate as safe practice guidelines or accreditation standards instead of performance metrics, adding that proceeding with these measures could lead to the endorsement of other device-related measures in the future.

The Steering Committee concurred with the measure developer by noting several well-publicized studies that indicated the potential for serious adverse health outcomes as a result of inadequate colonoscopy processing. The Committee reiterated that, as with all measures submitted to NQF, any future device-related measures would be evaluated against NQF's criteria for measure endorsement; therefore, endorsement of these colonoscopy measures would not automatically warrant the endorsement of future measures related to medical devices.

Use of dose indices for assessing radiation exposure and absorption (PSM-043-10 and PSM-044-10)

Both of the radiation safety measures submitted for this project use dose indices rather than actual dosing levels for each patient. Dose indices are calculations related to the amount of radiation generated to form an image. Several commenters asked for additional clarification on the relationship between dose indices and radiation absorption.

The developers noted that if dose indices are at optimal levels, then absorbed dose is also optimized. The Committee recognized the variability and difficulty in quantifying radiation levels and stressed what had been articulated by the measure developers in that dose indices allow for comparability and benchmarking of CT dosing levels, and are a reasonable basis for measurement and standardization.

Measure specific comments

Participation in a Systematic National Dose Index Registry (PSM-043-10)

There were a few comments that cautioned against a participation measure that simply captures registry participation and does not assess process to outcome.

NATIONAL QUALITY FORUM

The measure developer cited other registries in which registry participation drove improvement. The developer added that the registry will provide for consistent, standardized, automated data collection with anonymization of patient data and aggregated data available to sites through regular reports. This will eliminate the need for data entry and will reduce errors and burden. The Steering Committee reiterated the importance of capturing these facility-level data for standardization, benchmarking and to ultimately ensure safe output of radiation levels. The Committee acknowledged the variability of practice both within and between facilities.

Radiation Dose Computed Tomography (PSM-044-10)

Several comments questioned the rationale for not accounting for variability in body type and/or size when considering dosing levels.

The measure developer restated that these considerations are not relevant for the facility-level analysis required in the submitted measure. While patient size may influence dose by two to three-fold (between the smallest and largest patients), other factors, like choice of a specific protocol, have a much greater impact, influencing dose levels by up to 100 fold. Furthermore, facility-level variations would be determined by these factors, rather than individual patient weight. In addition, the measure calls for collecting dose information by age group, and thus there is no risk of inaccurate doses for child and adult patients.

Other comments specially addressed inclusion of dose indices in the medical record (part b) and usefulness of the data to providers and patients.

The measure developer asserted that doses used for CT are currently highly variable and doses are higher than they need to be for diagnostic accuracy. The purpose of this measure is to reduce both the variability of the doses used in clinical practice and reduce the magnitude of the doses used in clinical practice. These will be brought about by collection and assessment of doses, and a reduction in the doses will improve the safety of CT. Thus the measure will not only increase dose awareness, but by asking facilities to compare their doses to national standards, will encourage the creation of benchmarks for quality that will be widely implemented. This is a facility-level measure.

Initially, the Steering Committee recommended measure #PSM-044-10 for time-limited endorsement. Following the comment period and concerns raised about inclusion of dose indices in the medical report (part b) and the importance of patient weight in relation to appropriateness of dose for an individual patient, the Committee had additional discussions and considered public comments on the measures.

The Committee considered data provided by the developer from the University of California San Francisco that demonstrated ease of implementation and understanding and indicated increased demand for information by consumers and providers. The measure developer also noted that while patient size may influence dose by two to three-fold (between the smallest and largest patients), other factors, like choice of specific protocol, have a much greater impact, influencing dose levels by up to 100 fold, and added these considerations are not relevant for the facility-level analysis required under the measure.

Ultimately the Steering Committee voted to continue to recommend measure #PSM-044-10 for time-limited endorsement.

NATIONAL QUALITY FORUM

NQF Member Voting

Information for electronic voting was sent to NQF member organization primary contacts. Accompanying comments must be submitted by e-mail. The e-mail must identify submitter, organization, and the specific ballot item that the comments accompany.

All votes must be submitted no later than 6:00 pm ET, May 5, 2010.

Thank you for your interest in this consensus development project.

NATIONAL QUALITY FORUM

NATIONAL VOLUNTARY CONSENSUS STANDARDS FOR PATIENT SAFETY MEASURES, SECOND REPORT: A CONSENSUS REPORT

DRAFT REPORT FOR COMMENT

NQF REVIEW DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER comments due February 9, 2011, 6:00 PM ET; PUBLIC comments due February 2, 2011 by 6:00 PM ET

NATIONAL QUALITY FORUM

NATIONAL VOLUNTARY CONSENSUS STANDARDS FOR PATIENT SAFETY MEASURES, SECOND REPORT: A CONSENSUS REPORT

TABLE OF CONTENTS

Executive Summary	
Background	
Strategic Directions for NQF	
National Priorities Partnership	
NQF's Consensus Development Process	
Evaluating Potential Consensus Standards	
Candidate Consensus Standards Recommended for Time-limited Endorsement.....	
Candidate Consensus Standards Not Recommended for Endorsement.....	
Additional Recommendations	
Notes	
Appendix A—Specifications for the National Voluntary Consensus Standards for Patient Safety Measures, Second Report: A Consensus Report.....	A-1
Appendix B—Steering Committee, Technical Advisory Panels, and NQF Staff	B-1
Appendix C— NQF-Endorsed [®] Measures as of April 2010.....	C-1

NQF REVIEW DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER comments due February 9, 2011, 6:00 PM ET; PUBLIC comments due February 2, 2011 by 6:00 PM ET

NATIONAL QUALITY FORUM

NATIONAL VOLUNTARY CONSENSUS STANDARDS FOR PATIENT SAFETY MEASURES, SECOND REPORT: A CONSENSUS REPORT

1 EXECUTIVE SUMMARY

2 Americans are exposed to more preventable medical errors than patients in other industrialized
3 nations; medical errors within the United States health care system occur every day in the tens of
4 thousands and potentially hundreds of thousands. These errors cause injuries in as many as 1 out
5 of every 25 hospital patients and lead to an estimated 44,000-98,000 patient deaths annually. If
6 using low mortality estimates, medical errors would rank as the eighth leading cause of death in
7 the United States. Preventable errors cost the United States \$17-\$29 billion per year in healthcare
8 expenses, lost worker productivity, and disability. As healthcare expenditures grow at more than
9 seven percent each year, patient safety is improving by only one percent.

10
11 Adverse events can occur throughout the healthcare delivery system and can include medication
12 errors, surgical errors, diagnostic inaccuracies and system failures. In November 2008, the
13 National Priorities Partnership (NPP) named patient safety as one of the six national priorities,
14 with a specific focus on reduction of hospital-level mortality rates, serious adverse events, and
15 healthcare-associated infections (HAIs). Among the National Quality Forum's (NQF) inventory
16 of 550 endorsed measures, over 100 measures relate to patient safety. NQF's recent Patient
17 Safety Measures project solicited measures to fill gap areas and to address environment-specific
18 issues with the highest potential leverage for improvement. The first report of the Patient Safety
19 Measures project focused specifically on HAIs, urinary tract infections (UTIs), surgical site
20 infections (SSIs), and bloodstream infection measures. This second report focuses on a broad
21 range of safety issues, including measures that address medication safety, colonoscopy
22 processing, querying and counseling on side-effects, and radiation dosing. It is important to note
23 that none of the medication safety or querying and counseling measures are recommended for
24 endorsement.

25
26 The NQF Steering Committee reviewed the submitted patient safety measures and recommended
27 the measures that they considered to have the potential for broad and far-reaching impact. The
28 Steering Committee further based their recommendations on significant evidence that

NQF REVIEW DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER comments due February 9, 2011, 6:00 PM ET; PUBLIC comments due February 2, 2011 by 6:00 PM ET

NATIONAL QUALITY FORUM

29 implementation would reduce mortality or mitigate severe harm. Ultimately, the Steering
30 Committee stated that NQF endorsement should signify the importance of allocating resources to
31 collect and report on these measures.

32
33 In this second report of NQF's Patient Safety Measures project, five measures are recommended
34 for endorsement as voluntary consensus standards suitable for public reporting and quality
35 improvement. All of these measures are recommended for time-limited endorsement. These
36 measures were submitted by the AAAHC Institute for Quality Improvement, American College
37 of Radiology (ACR), and the University of California San Francisco. The measures are listed
38 below:

39

40 **RECOMMENDATIONS FOR TIME-LIMITED ENDORSEMENT**

- 41 • PSM-014-10: Colonoscopy processing personnel instruction (AAAHC Institute for
42 Quality Improvement)
- 43 • PSM-015-10: Colonoscopy processing currency (AAAHC Institute for Quality
44 Improvement)
- 45 • PSM-016-10: Colonoscopy processing competency (AAAHC Institute for Quality
46 Improvement)
- 47 • PSM-043-10 - Participation in a systematic national dose index registry (ACR)
- 48 • PSM-044-10 - Radiation dose computed tomography (CT) (University of California San
49 Francisco)

50

NATIONAL QUALITY FORUM

NATIONAL VOLUNTARY CONSENSUS STANDARDS FOR PATIENT SAFETY, SECOND REPORT: A CONSENSUS REPORT

51 BACKGROUND

52 Americans are exposed to more preventable medical errors than patients in other industrialized
53 nations; medical errors within the United States health care system occur every day in the tens of
54 thousands and potentially hundreds of thousands.¹ These errors cause injuries in as many as 1 out
55 of every 25 hospital patients and lead to an estimated 44,000-98,000 patient deaths annually. If
56 using the low mortality estimates, medical errors would rank as the eighth leading cause of death
57 in the United States. Preventable errors cost the United States \$17-\$29 billion per year in
58 healthcare expenses, lost worker productivity, and disability. As healthcare expenditures grow at
59 more than seven percent each year, patient safety is improving by only one percent.²

60 Adverse events can occur throughout the healthcare delivery system and include medication
61 errors, surgical errors, diagnostic inaccuracies and system failures.³ In November 2008, the
62 National Priorities Partnership (NPP) named patient safety as one of the six national priorities,
63 with specific focus on reduction of hospital-level mortality rates, serious adverse events, and
64 healthcare-associated infections (HAIs).

65 Due to the high impact and widespread incidence of medical errors, interest in measurement and
66 reporting of such events has increased among consumers, providers, purchasers, and oversight
67 organizations. Measurement drives improvement and informs consumers and payers, all of
68 which are imperative for improving patient safety and decreasing medical errors.⁴

69 The National Quality Forum (NQF) has produced an array of products that focus on measuring,
70 evaluating, reporting, and preventing patient safety events. Presently, NQF has endorsed over
71 100 performance measures that are directly related to patient safety. These endorsed measures
72 are relevant in several different environments of care (e.g., hospitals, ambulatory care, and long-
73 term care) as well as applicable to a variety of healthcare professionals (e.g., physicians, nurses).
74 In 2002, NQF first published a list of 27 adverse events in its report *Serious Reportable Events in*
75 *Healthcare*, designating these events as important for public reporting at the state and national

NQF REVIEW DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER comments due February 9, 2011, 6:00 PM ET; PUBLIC comments due February 2, 2011 by 6:00 PM ET

NATIONAL QUALITY FORUM

76 levels, with the aims of facilitating education about the events and developing strategies for
77 prevention of the events.⁵ NQF's *Safe Practices for Better Healthcare*, first published in 2003,
78 identifies best practices for improving the safety and quality of healthcare delivered.⁶

79
80 NQF's Patient Safety Measures project solicited measures to fill gap areas and to address
81 environment-specific issues with the highest potential leverage for improvement such as HAIs,
82 culture of safety, and hospital standardized mortality rates. This project was divided into two
83 separate but related phases. The initial phase of the Patient Safety Measures project focused
84 specifically on HAIs, urinary tract infections (UTIs), surgical site infections (SSIs), and
85 bloodstream infections. The second phase of the Patient Safety Measures project focuses on a
86 broad range of safety issues including measures that address medication safety, colonoscope
87 processing, querying and counseling on side-effects, and radiation dosing.

88 The Steering Committee recommended measures with a strong evidence base that demonstrated
89 that implementation would reduce patient mortality and/or harm. The Steering Committee also
90 stated that NQF endorsement should signify the importance of allocating resources to both
91 measure and publicly report; additionally, measures that lacked rigorous evidence in support of
92 an outcome were not recommended for endorsement.

93 STRATEGIC DIRECTIONS FOR NQF

94 NQF's mission includes three parts: 1) building consensus on national priorities and goals for
95 performance improvement and working in partnership to achieve them; 2) endorsing national
96 consensus standards for measuring and publicly reporting on performance; and 3) promoting the
97 attainment of national goals through education and outreach programs. As greater numbers of
98 quality measures are developed and brought to NQF for consideration of endorsement, it is
99 incumbent on NQF to assist stakeholders to "measure what makes a difference" and address
100 what is important to achieve the best outcomes for patients and populations. For more
101 information, see www.qualityforum.org.

102
103 Several strategic issues have been identified to guide consideration of candidate consensus
104 standards:

NATIONAL QUALITY FORUM

105 **DRIVE TOWARD HIGH PERFORMANCE.** Over time, the bar of performance expectations
106 should be raised to encourage the achievement of higher levels of system performance.

107 **EMPHASIZE COMPOSITES.** Composite measures provide much needed summary
108 information pertaining to multiple dimensions of performance and are more comprehensible to
109 patients and consumers.

110 **MOVE TOWARD OUTCOME MEASUREMENT.** Outcome measures provide information
111 of keen interest to consumers and purchasers, and when coupled with healthcare process
112 measures, they provide useful and actionable information to providers. Outcome measures also
113 focus attention on much needed system-level improvements, because achieving the best patient
114 outcomes often requires carefully designed care processes, teamwork, and coordinated action on
115 the part of many providers.

116 **CONSIDER DISPARITIES IN ALL THAT WE DO.** Some of the greatest performance gaps
117 relate to care of minority populations. Particular attention should be focused on the most relevant
118 race/ethnicity/language/socioeconomic strata to identify relevant measures for reporting.

119

120 **NATIONAL PRIORITIES PARTNERSHIP**

121 NQF seeks to endorse measures that address the National Priorities and Goals of the National
122 Priorities Partnership.⁷ The National Priorities Partnership represents those who receive, pay for,
123 provide, and evaluate healthcare. As of 2010, the National Priorities and Goals focus on these
124 eight areas:

- 125 • patient and family engagement,
- 126 • population health,
- 127 • safety,
- 128 • care coordination,
- 129 • palliative and end-of-life care,
- 130 • overuse,
- 131 • equitable access, and
- 132 • infrastructure support.

133

134

NQF REVIEW DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER comments due February 9, 2011, 6:00 PM ET; PUBLIC comments due February 2, 2011 by 6:00 PM ET

NATIONAL QUALITY FORUM

135 NQF'S CONSENSUS DEVELOPMENT PROCESS (CDP)

136 Patient Safety Measures Project⁸

137 The National Quality Forum's National Voluntary Consensus Standards for Patient Safety
138 Measures project seeks to endorse patient safety-related measures that address healthcare-
139 associated infections (HAIs), medication safety, and other areas. Potential consensus standards
140 focus on a broad range of areas including but not limited to safety risk assessment and/or risk
141 identification, hospital standardized mortality rates, reporting and follow-up or critical test
142 results, and leadership and culture of safety.

143
144 The full constellation of consensus standards, along with those presented in this report, provide a
145 growing number of NQF-endorsed[®] voluntary consensus standards that directly reflect the
146 importance of measuring and improving the quality of care provided to patients. Organizations
147 that adopt these consensus standards will promote the delivery of safer and higher-quality care
148 for patients.

149

150 Evaluating Potential Consensus Standards

151 Candidate standards were solicited through an open "Call for Measures" in January 2010 and
152 were actively sought by NQF staff through literature reviews, a search of the National Quality
153 Measures Clearinghouse, NQF Member websites, and an environmental scan. The measures
154 were evaluated using NQF's standard evaluation criteria.⁹ Technical Advisory Panels (TAPs)
155 related to HAIs and medication safety measures rated the subcriteria for each candidate
156 consensus standard and identified strengths and weaknesses to assist the Steering Committee
157 (Committee) in making recommendations. (The HAI measures were presented in an earlier
158 report [— that report has been delayed in order to accommodate efforts to harmonize two](#)
159 [potentially competing measures that were submitted under this project.](#)) For this second report,
160 the 21-member, multi-stakeholder Committee provided final evaluations of the four main
161 criteria: importance to measure and report, scientific acceptability of the measure properties,
162 usability, and feasibility. Measure developers participated in the TAP and Steering Committee
163 discussions to respond to questions and clarify any issues or concerns.

164

NQF REVIEW DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER comments due February 9, 2011, 6:00 PM ET; PUBLIC comments due February 2, 2011 by 6:00 PM ET

NATIONAL QUALITY FORUM

165

166

167 **RECOMMENDATIONS FOR ENDORSEMENT**

168 This second report of the Patient Safety Measures project presents the evaluation results of
169 twenty-one medication safety, querying and counseling on side-effects, colonoscopy, and
170 radiation dosing measures considered under NQF's Consensus Development Process. Five
171 measures are recommended for endorsement as voluntary consensus standards suitable for public
172 reporting and quality improvement. All of these measures are recommended for time-limited
173 endorsement.

174

175 **Candidate Consensus Standards Recommended for Endorsement**

176

177 ***Colonoscopy Measures***

178

179 **PSM-014-10: Colonoscopy processing personnel instruction (AAAHC Institute for Quality**
180 **Improvement)** *Percentage of all colonoscopy reprocessing personnel at ambulatory surgery*
181 *centers and office-based practices who receive device-specific instructions at least annually, as*
182 *well as whenever any changes are made in colonoscopy equipment or in manufacturers'*
183 *recommendations, to ensure proper colonoscopy reprocessing **grouped¹⁰ with PSM-015-10:***
184 **Colonoscopy processing currency (AAAHC Institute for Quality Improvement)** *Whether or*
185 *not ambulatory surgery centers and office-based practices performing colonoscopies review*
186 *national device-specific reprocessing guidelines and manufacturers' recommendations for*
187 *reprocessing colonoscopes at least annually (every 12 months), as well as whenever any changes*
188 *are made in colonoscopy equipment or in manufacturers' recommendations, and revise their*
189 *policies and procedures to incorporate any changes that have occurred, **and PSM-016-10:***
190 **Colonoscopy processing competency (AAAHC Institute for Quality Improvement)**
191 *Percentage of all colonoscopy reprocessing personnel at ambulatory surgery centers and office-*
192 *based practices who are documented to be competent at reprocessing colonoscopes on initial*
193 *assignment and at least annually thereafter, as well as whenever any changes are made in*
194 *colonoscopy equipment or in manufacturers' recommendations.*

NQF REVIEW DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER comments due February 9, 2011, 6:00 PM ET; PUBLIC comments due February 2, 2011 by 6:00 PM ET

NATIONAL QUALITY FORUM

195 All of these measures are recommended for time-limited endorsement.

196

197 Although each measure was evaluated independently, Steering Committee members believed
198 that grouping all three measures together would result in a more comprehensive assessment of
199 colonoscopy processing. Because several issues raised by the Committee cut across the
200 specifications for all three measures, the discussion and recommendations for the measures are
201 presented jointly.

202

203 Colonoscopy is the most frequently performed procedure in ambulatory care settings. The
204 measure developer cited data that indicated low compliance with proper reprocessing procedures.
205 The data also demonstrated that the vast majority of viral outbreaks from this procedure have
206 been linked to improper cleaning techniques. Other adverse outcomes related to improper
207 colonoscopy reprocessing include patient apprehension of future colonoscopy screening and the
208 institutional cost of financial liability for negligence.¹¹ Incorporating current national and
209 manufacturer recommendations into colonoscopy processing policies and procedures is likely to
210 significantly reduce the adverse health and other effects associated with improper reprocessing.
211 For these reasons, the Committee agreed that these measures strongly meet the criteria of
212 importance to measure and report.

213

214 Emphasizing further the importance of ensuring proper colonoscopy reprocessing, several
215 Committee members advocated for increased rigor in assessing reprocessing standards, including
216 but not limited to regulation and state licensing initiatives. The developer noted these
217 recommendations and suggested that endorsement of the three performance measures would be a
218 critical step towards expansion of colonoscopy reprocessing compliance standards in other
219 realms.

220

221 While the Committee appreciated the detail within the specifications, members requested
222 clarification on the differences between existing standards required as part of ambulatory
223 surgical centers' accreditation process and these performance metrics. The developer explained
224 that compliance with accreditation standards is determined through surveys and typically

NQF REVIEW DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER comments due February 9, 2011, 6:00 PM ET; PUBLIC comments due February 2, 2011 by 6:00 PM ET

NATIONAL QUALITY FORUM

225 involves an element of equipment maintenance. By contrast, these performance measures
226 incorporate an element of accountability and include a reporting requirement, which allows for a
227 greater degree of granularity for assessing performance.

228
229 The Committee strongly believed that these measures should have application beyond the
230 ambulatory care setting (i.e. office-based practices). The developer explained that the setting was
231 initially specified in response to the Tax Relief and Health Care Act of 2006, in which Congress
232 mandated that the surveillance of ambulatory care facilities be comparable to what was mandated
233 earlier for hospitals.

234
235 Following lengthy discussion about initial training and competency, the Committee
236 recommended that the developer remove the word “current” to accommodate changes in
237 equipment or recommendations from the manufacturer. The Committee further recommended
238 that personnel competency should be assessed following those changes. In response to the
239 Committee’s suggestions, the developer added office-based practice (OBP) to the denominator
240 population. The developer also removed the word “current” from the measure specifications for
241 each measure and added the following wording, “as well as whenever any changes are made in
242 colonoscope equipment or manufacturers’ recommendations.”

243
244 During the public comment period, a number of commenters questioned whether these measures
245 would be more appropriate as safe practice guidelines or accreditation standards instead of
246 performance metrics, adding that proceeding with these measures could lead to the endorsement
247 of other device-related measures in the future.

248
249 Noting several well-publicized studies that indicated the potential for serious adverse health
250 outcomes as a result of inadequate colonoscopy processing, the Steering Committee determined
251 that there was a need for publicly-reported measures in this area, and upheld its recommendation
252 for endorsement. The Committee reiterated that, as with all measures submitted to NQF, any
253 future device-related measures would be evaluated against NQF’s criteria for measure

NATIONAL QUALITY FORUM

254 | endorsement; therefore, endorsement of these colonoscopy measures would not automatically
255 | warrant the endorsement of future measures related to medical devices.

256

257 The Steering Committee accepted the modifications as specified and agreed that these measures
258 met the criteria for scientific acceptability, feasibility, and usability. The Committee
259 recommended these measures, as a group, for time-limited endorsement in a unanimous vote.
260 These measures address the National Priority of safety.

261

262 ***Radiation Dosing Measures***

263

264 Measurement of radiation dosing and radiation exposure from computed tomography (CT) scans
265 is a difficult and complicated undertaking. Dosing levels are not easily quantified, and radiation
266 absorption rates can vary significantly between organs and between patients. In combination
267 with a lack of standardization in terminology (different facilities may have very different naming
268 conventions for the scans they perform) and other variations in practice, these factors can
269 confound attempts to gauge the extent of radiation exposure, either for a particular patient or at a
270 broader public health level.

271

272 Because of the difficulties involved in measuring radiation exposure and absorption, both of the
273 radiation safety measures submitted for this project use dose indices rather than actual dosing
274 levels for each patient. Dose indices, such as “volume CT dose index” (CTDI_{vol}) or “dose-
275 length product” (DLP), are calculations related to the amount of radiation generated to form an
276 image. Nearly all CT machines are able to document and provide a dose index for any given
277 scan. Several concerns were raised during the commenting period about the relationship between
278 measured dose indices and the amount of radiation absorbed by patients. The Committee
279 maintained that dose indices do allow for comparability and benchmarking of CT dosing levels,
280 and are a reasonable basis for measurement efforts. ▼

281

282 **PSM-043-10: Participation in a systematic national dose index registry (American College**
283 **of Radiology) *Participation in a multi-center, standardized data collection and feedback***

Deleted: While dose indices are not directly related to the amount of radiation absorbed by patients, they may allow for comparability and benchmarking of CT dosing levels.

NQF REVIEW DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER comments due February 9, 2011, 6:00 PM ET; PUBLIC comments due February 2, 2011 by 6:00 PM ET

NATIONAL QUALITY FORUM

288 *program that will establish national dose index benchmarks for designated examinations. The*
289 *registry will eventually provide a comparison of practice or facility dose indices such as*
290 *CTDIvol and DLP for specified examinations relative to national and regional benchmarks.*
291 *Data is captured electronically from the images of CT examinations using Digital Imaging and*
292 *Communications in Medicine (DICOM) standards and the Integrating the Healthcare Enterprise*
293 *(IHE) Radiation Exposure Monitoring (REM) profile.*

294

295 This measure is recommended for time-limited endorsement.

296

297 This is strictly a participation measure, requiring only a yes/no answer: does the reporting facility
298 participate in a national dose index registry or not? Specifically, the measure assesses whether or
299 not a facility or practice participates in a systematic, multi-center, standardized data collection
300 program. The American College of Radiology (ACR) has established its own National Dose
301 Index Registry (NDIR), which is in the midst of a second pilot run and is anticipated to be ready
302 for use by mid- to late 2011. However, if any other organization or entity were to develop a
303 systematic, standardized CT dose registry, participation in such a registry would also fulfill the
304 measure's requirements.

305

306 The measure developers emphasized that their aim is not just to drive radiation levels down, but
307 also to address the need to produce images that are detailed enough to allow successful
308 interpretations or diagnoses. The developer cited the Society of Thoracic Surgeons National
309 Adult Cardiac Database and the Breast Cancer Surveillance Consortium as examples of registry
310 participation that are associated with quality improvements, and noted that performance
311 improvement had already been observed within the ACR registry pilot program.

312

313 The Steering Committee agreed that this measure met the criterion of importance to measure and
314 report. Committee members discussed whether implementation of the measure was feasible for a
315 large percentage of facilities, noting that electronic picture archiving and communication systems
316 (PACS), where CT images and associated data are stored, have a high penetration rate in

NQF REVIEW DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER comments due February 9, 2011, 6:00 PM ET; PUBLIC comments due February 2, 2011 by 6:00 PM ET

NATIONAL QUALITY FORUM

317 radiology practices. The Committee agreed that the reporting required for this measure could be
318 done by a fairly high number of institutions with relatively little burden.

319

320 The Steering Committee agreed that the measure met the criteria for scientific acceptability,
321 feasibility, and usability, and recommended the measure for time-limited endorsement in a
322 unanimous vote. This measure addresses the National Priority of safety.

323

324 **PSM-044-10: Radiation dose of computed tomography (University of California San**
325 **Francisco)** *The measure has two components. Part A is an outcome measure; Part B is a*
326 *process measure. Both would work together towards improving quality and allowing hospitals*
327 *and imaging facilities to conduct ongoing quality improvement. Part A: radiation dose*
328 *associated with computed tomography (CT) examinations of the head, neck, chest,*
329 *abdomen/pelvis, and lumbar spine, obtained in children and adults. Part B: The proportion of*
330 *CT examinations where a measure of dose is included in the final medical report.*

331

332 This measure would first require CT scan providers to record the dose index (CTDIvol, DLP, or
333 “effective dose”—an estimate based on DLP and other factors) for a consecutive sample of CTs
334 conducted in the head, chest, abdomen/pelvis, and lumbar spine. Under the second part of the
335 measure, these dose indices would be required to be included in patients’ final medical reports.
336 The minimum sample size for this measure to generate sufficient accuracy for adults is 100
337 scans; the minimum sample size for children is 50. Because different facilities will reach these
338 thresholds at different rates, the time window for the measure’s numerator may vary depending
339 on the number of scans done at a facility.

340

341 Responding to concerns from the Committee about whether patients and non-radiology
342 providers—the intended users—could use the measure, the developer stated that increased
343 transparency around dosing information is important for fostering accountability and driving
344 improvement; furthermore, inclusion of dose indices in the final medical report was the simplest,
345 most concrete way for a patient or ordering physician to evaluate CT dosing information. The
346 developer added that collecting this information outside of the radiology department will create

NQF REVIEW DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER comments due February 9, 2011, 6:00 PM ET; PUBLIC comments due February 2, 2011 by 6:00 PM ET

NATIONAL QUALITY FORUM

347 better incentives and will allow information tracking over time. A number of concerns were also
348 raised during the public and member commenting period regarding usability for patients and
349 referring physicians. In response to submitted comments, further discussions were held on this
350 subject, with the measure developer presenting additional information to support the measure.

351 Some Committee members expressed discomfort with endorsing a measure where there appears
352 to be disagreement among experts as to its readiness for use at a national level. However, other
353 Committee members thought that a sufficient case had been made for the measure, stating that,
354 given the clear need for increased transparency in radiation dosing levels and the importance of
355 reducing radiation exposure from CT scans, providing metrics to assist with these efforts was of
356 greater urgency.

357

358 The Steering Committee ultimately agreed that the measure met the criteria for scientific
359 acceptability, usability, and feasibility, and recommended the measure for time-limited
360 endorsement. This measure addresses the National Priority of safety.

361

362 ***Comparison of Radiation Dosing Measures (#PSM-043-10 and #PSM-044-10)***

363

364 Both of the radiation safety measures submitted for this project share the ultimate goal of
365 achieving safer patient care through reduced variation in CT scan doses and the use of more
366 appropriate CT dosing levels. However, the measure developers differ notably in their
367 approaches and in their proximate goals regarding the use of data generated through their
368 measures. Measure #PSM-043-10 is currently specified to facilitate internal safety improvement
369 efforts by CT scan providers. There is a public reporting component by which aggregate registry
370 data will be published periodically; in addition, facilities will receive feedback to enable them to
371 compare their dosing levels with regional or national averages. Measure #PSM-044-10 has a
372 more direct public reporting component that requires dosing information be included in the final
373 medical report, so that it is accessible to patients and primary care providers or other ordering
374 physicians.

375

NATIONAL QUALITY FORUM

376 The Steering Committee noted that these two measures are complementary, and suggested that
377 the measures could potentially lend themselves to a “stepwise” process—meaning measure
378 #PSM-044-10, which could be implemented fairly rapidly, could be used to collect and review
379 dosing information at the patient care level, increase awareness of dosing levels, and provide
380 incentives for improvement. The same data could then be incorporated into a national registry to
381 enable comparisons and tracking of trends at the population level once measure #PSM-043-10
382 became more fully and widely implemented. For these reasons, the Committee unanimously
383 agreed that harmonization¹² of the measures was not warranted.

384

385 **Candidate Consensus Standards Not Recommended for Endorsement**

386

387 The following measures have been divided into two topic areas—querying and counseling on
388 side-effects measures and medication safety measures. Several of the issues raised by the
389 Steering Committee cut across the specifications for all measures within each topic area;
390 therefore, the discussion and recommendations for each are presented jointly. With the exception
391 of PSM-010-10: Querying and counseling about anti-epileptic drug (AED) side-effects, none of
392 these candidate standards met the threshold for importance to measure and report. Each measure
393 was evaluated independently against NQF’s evaluation criteria on importance. The Committee
394 grounded their final recommendations on the degree to which the impact, opportunity for
395 improvement, and evidence were demonstrated for each measure. The Committee encourages
396 additional measure development in these areas and has outlined several recommendations in this
397 section and under “Additional Recommendations.”

398

399 ***Querying and Counseling on Side-effects Measures***

400

401 **PSM-010-10: Querying and counseling about anti-epileptic drug (AED) side-effects**
402 **(American Academy of Neurology)** *Percentage of patient visits for patients with a diagnosis of*
403 *epilepsy where the patients were queried and counseled about anti-epileptic drug (AED) side-*
404 *effects and the querying and counseling was documented in the medical record.*

405

NQF REVIEW DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER comments due February 9, 2011, 6:00 PM ET; PUBLIC comments due February 2, 2011 by 6:00 PM ET

NATIONAL QUALITY FORUM

406 **PSM-011-10: Counseling about epilepsy specific safety issues (American Academy of**
407 **Neurology)** *Percentage of patients with diagnosis of epilepsy (or their caregiver(s)*
408 *counseled about context-specific safety issues, appropriate to the patient's age, seizure type(s)*
409 *and frequency(ies), occupation and leisure activities, etc. (e.g., injury prevention, burns,*
410 *appropriate driving restrictions, or bathing) at least once a year.*

411

412 **PSM-012-10: Querying about falls (Parkinson's disease patients) (American Academy of**
413 **Neurology)** *Percentage of visits for patients with a diagnosis of Parkinson's disease where the*
414 *patients (or caregiver(s), as appropriate) were queried about falls.*

415

416 **PSM-013-10: Parkinson's disease related safety issues counseling (American Academy of**
417 **Neurology)** *Percentage of patients with a diagnosis of Parkinson's disease (or caregiver(s), as*
418 *appropriate) who were counseled about context-specific safety issues appropriate to the patient's*
419 *stage of disease (e.g., injury prevention, medication management, or driving) at least annually.*

420

421 These process measures were developed for inclusion in the AAN Maintenance of Certification
422 Performance in Practice Toolkit (currently under development), to assess an element of treatment
423 for non-stroke and non-stroke rehabilitation neurologic conditions. While the Committee
424 recognized the importance of educating epilepsy and Parkinson's disease patients about
425 medication management, falls, and context-specific safety issues, they voiced several universal
426 concerns about these measures including the lack of specificity related to performance gaps and
427 linkages to outcomes, and the reliance on consensus-based clinical practice guidelines.

428

429 Measure #PSM-010-10: Querying and counseling about anti-epileptic drug (AED) side-effects,
430 is the only metric within the measure set that captures both querying and counseling. Although
431 this measure met the threshold for importance to measure and report, Committee members
432 questioned why the measure was limited to physicians, and noted that advanced practice nurses
433 and pharmacists, for example, also query and counsel patients on AED side effects. The
434 Committee suggested that the developer expand application of the measure to include services

NQF REVIEW DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER comments due February 9, 2011, 6:00 PM ET; PUBLIC comments due February 2, 2011 by 6:00 PM ET

NATIONAL QUALITY FORUM

435 provided by “physician extenders” (i.e., advanced practice nurses, clinical pharmacists, and other
436 advanced care providers). The developer agreed to include physician extenders in the measure.

437

438 The measure includes only those patients with a principal diagnosis of epilepsy. The
439 specifications were modified to make this clearer. In response to the Committee’s concern about
440 how the developer intended to qualify “querying and counseling”, the developer revised the
441 specifications to include explicit examples of querying and counseling.

442

443 The Committee appreciated the developer’s efforts but did not believe that these modifications
444 sufficiently addressed their concerns and did not recommend this measure for endorsement. The
445 developer requested a reconsideration of the measure, asking for an opportunity to present
446 additional information and more fully respond to the Steering Committee’s concerns. The
447 Committee held further discussions on the measure, but upheld its decision not to recommend
448 the measure for endorsement. No public comments were submitted on this measure.

449

450 **Medication Safety Measures**

451

452 **PSM-017-10: Patient(s) with rheumatoid arthritis taking methotrexate, sulfasalazine, or**
453 **leflunomide that had serum ALT or AST test in last 3 reported months (Ingenix, Inc.)** *This*
454 *measure identifies individuals with rheumatoid arthritis, 2 years of age or older, taking*
455 *methotrexate, sulfasalazine, or leflunomide that had a serum ALT/AST test in last 3 months of the*
456 *report period.*

457

458 **PSM-018-10: Patient(s) with rheumatoid arthritis taking methotrexate or sulfasalazine that**
459 **had a serum creatinine in last 6 reported months (Ingenix, Inc.)** *This measure identifies*
460 *individuals with rheumatoid arthritis, 2 years of age or older, taking methotrexate or*
461 *sulfasalazine that had a serum creatinine test in last 6 months of the report period.*

462

463 **PSM-019-10: Patient(s) with rheumatoid arthritis taking methotrexate, sulfasalazine, gold,**
464 **or leflunomide that had a CBC in last 3 reported months (Ingenix, Inc.)** *This measure*

NQF REVIEW DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER comments due February 9, 2011, 6:00 PM ET; PUBLIC comments due February 2, 2011 by 6:00 PM ET

NATIONAL QUALITY FORUM

465 *identifies individuals with rheumatoid arthritis, 2 years of age or older, taking methotrexate,*
466 *sulfasalazine, gold, or leflunomide that had a CBC test in last 3 months of the report period.*

467

468 **PSM-020-10: Patient(s) with inflammatory bowel disease taking methotrexate,**
469 **azathioprine, or mercaptopurine that had serum ALT or AST test in last 6 reported**
470 **months (Ingenix, Inc.)** *This measure identifies individuals with inflammatory bowel disease, 12*
471 *years of age or older, taking methotrexate, azathioprine, or mercaptopurine that had a serum*
472 *ALT/AST test in last 6 months of the report period.*

473

474 **PSM-021-10: Adult patient(s) with multiple sclerosis taking interferon that had a serum**
475 **ALT/AST test in last 12 reported months (Ingenix, Inc.)** *This measure identifies adults with*
476 *multiple sclerosis taking interferon that had at least one serum ALT/AST test in last 12 months of*
477 *the report period.*

478

479 **PSM-022-10: Adult patient(s) with multiple sclerosis taking interferon that had a CBC in**
480 **last 12 reported months (Ingenix, Inc.)** *This measure identifies adults with multiple sclerosis*
481 *taking interferon that had at least one CBC test in last 12 months of the report period.*

482

483 **PSM-023-10: Patient(s) with hepatitis C infection taking interferon that had periodic**
484 **serum ALT monitoring (Ingenix, Inc.)** *This measure identifies hepatitis C virus (HCV) infected*
485 *persons, 3 years of age or older, taking interferon that had at least two serum tests in last 6*
486 *months of the report period.*

487

488 **PSM-024-10: Patient(s) with hepatitis C infection taking interferon that had periodic CBC**
489 **with differential monitoring (Ingenix, Inc.)** *This measure identifies hepatitis C virus (HCV)*
490 *infected persons, 3 years of age or older, taking interferon that had at least two CBCs with*
491 *differential tests in last 6 months of the report period.*

492

493 **PSM-025-10: Patient(s) with HIV infection taking antiretroviral medications that had a**
494 **serum ALT or AST test in last 6 reported months (Ingenix, Inc.)** *This measure identifies*

NQF REVIEW DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER comments due February 9, 2011, 6:00 PM ET; PUBLIC comments due February 2, 2011 by 6:00 PM ET

NATIONAL QUALITY FORUM

495 *HIV-infected persons, 2 years of age or older, taking antiretroviral medications that had at least*
496 *one serum ALT or AST test in last 6 months of the report period.*

497

498 **PSM-026-10: Patient(s) with HIV infection taking antiretroviral medications that had a**
499 **CBC in last 6 reported months (Ingenix, Inc.)** *This measure identifies HIV-infected persons, 2*
500 *years of age or older, taking antiretroviral medications that had at least one CBC test in last 6*
501 *months of the report period.*

502

503 **PSM-030-10: Patient(s) with inflammatory bowel disease taking methotrexate,**
504 **sulfasalazine, mercaptopurine, or azathioprine that had a CBC in last 3 reported months**
505 **(Ingenix, Inc.)** *This measure identifies individuals with inflammatory bowel disease, 12 years of*
506 *age or older, taking methotrexate, sulfasalazine, mercaptopurine, or azathioprine that had a*
507 *CBC test in last 3 months of the report period.*

508

509 **PSM-031-10: Patient(s) with inflammatory bowel disease taking methotrexate that had a**
510 **serum creatinine in last 6 reported months (Ingenix, Inc.)** *This measure identifies individuals*
511 *with inflammatory bowel disease, 12 years of age or older, taking methotrexate that had a serum*
512 *creatinine test in last 6 months of the report period.*

513

514 These process measures focus on medication safety issues related to rheumatoid arthritis,
515 inflammatory bowel disease, multiple sclerosis, hepatitis C, HIV, and routine laboratory
516 monitoring for specific adverse events. As with the querying and counseling measures,
517 Committee members were concerned that evidence-base for the measures was derived from
518 consensus and not from formal epidemiologic studies or trials that assessed toxicities of these
519 medications and monitoring frequencies. For example, while there is wide agreement for the
520 need for medication monitoring for methotrexate, sulfasalazine, and leflunomide (drugs used to
521 treat rheumatoid arthritis), the frequency of monitoring has not been widely agreed on or based
522 on evidence.

523 The Steering Committee also questioned the variation in the reporting period time window
524 across the measures. The developer explained that these timeframes were defined as written to

NQF REVIEW DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER comments due February 9, 2011, 6:00 PM ET; PUBLIC comments due February 2, 2011 by 6:00 PM ET

NATIONAL QUALITY FORUM

525 accommodate different guidelines from specialty societies. Another overarching issue identified
526 by the Committee was the apparent limited focus of each measure and condition. Many of these
527 measures are considered high volume but not high impact for patients. The incidence of harm
528 was deemed relatively low and monitoring medications within the defined time windows was not
529 indicative of better patient care.

530

531 The Committee acknowledged the difficulties and challenges in developing and evaluating these
532 measures, and commended the developer for contributing to this area of patient safety. Members
533 also encouraged the developer’s continued work with specialty societies for future measure
534 development. The Committee suggested that agreement on appropriate time windows for
535 monitoring medication use and strong empirical evidence of impact would further strengthen
536 these measures. Finally, the Committee advocated for the creation of broader measures with far
537 reaching impact on patient health outcomes. More information is included in the “Additional
538 Recommendations” section.

539

540

NQF REVIEW DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER comments due February 9, 2011, 6:00 PM ET; PUBLIC comments due February 2, 2011 by 6:00 PM ET

NATIONAL QUALITY FORUM

541 **Additional Recommendations**

542

543 The Steering Committee discussed future areas of focus for measurement, particularly related to
544 medication safety. Committee members expressed an interest in assessing broader, more cross-
545 cutting measures of medication safety or, alternatively, “templates” for medication management
546 and safety that could be applied to different medications or conditions. The Committee was also
547 interested in more research on standard medication monitoring and its effect on outcomes or
548 complications. Committee members thought that Ingenix’s set of measures, for example, could
549 be useful as a basis for comparative effectiveness studies focused on prevention of
550 complications.

551

552 In addition, Committee members challenged the current way of thinking about quality
553 improvement by placing measures within a certain spectrum related to their intended use or their
554 relevance for different objectives within health care. The Committee suggested categorizing
555 measures into classes or tiers based on their place in this spectrum. For instance, standards could
556 be split into three groups: 1) measures suitable for public accountability and reporting; 2)
557 measures geared towards quality improvement; and 3) practice guidelines, or baseline standards
558 of care. The Steering Committee recommended further study of this idea and possible
559 development of a framework or system for classifying measures.

560

561 During the initial stages of this project, a perinatal TAP was convened to consider a set of
562 measures forming a composite index for adverse outcomes in perinatal care. After discussion
563 between the measure developer and the TAP co-chairs, the set of perinatal measures was
564 ultimately withdrawn. However, perinatal TAP members convened via conference call to
565 identify gaps in perinatal care measurement and to offer thoughts on potential areas of focus in
566 the future.

567

568 The TAP members noted the following gap areas in NQF’s perinatal measures portfolio:

569

- 570 • Measures that assess quality of care during the labor and delivery process;

NQF REVIEW DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER comments due February 9, 2011, 6:00 PM ET; PUBLIC comments due February 2, 2011 by 6:00 PM ET

NATIONAL QUALITY FORUM

- 571 • Measures that assess quality and optimal care administered (e.g., of women who indicate
572 a desire to breastfeed, how many are given instructions prior to discharge);
- 573 • Measures of appropriateness of care for women who do not require extensive
574 intervention;
- 575 • Meaningful maternal outcome measures;
- 576 • New onset conditions that women experience in the first 2 months after hospital
577 discharge;
- 578 • New onset conditions that women experience in the first 6 months after hospital
579 discharge;
- 580 • Readmission following delivery and postpartum readmission measures;
- 581 • Measures that address disparities, care coordination and shared decision-making; and
- 582 • Full-term newborns that are discharged with or without complications.

583

584 The TAP noted that NQF's current set of perinatal measures is focused primarily at the facility-
585 level and acknowledged that these data are easily attainable and accessible. Nonetheless, they
586 encouraged a broader focus for future measure development.

587

NQF REVIEW DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER comments due February 9, 2011, 6:00 PM ET; PUBLIC comments due February 2, 2011 by 6:00 PM ET

NATIONAL QUALITY FORUM

588 NOTES

- 589 1. The Institute of Medicine: Achieving a New Standard for Care (2004). IOM; 2010.
590 Available at http://www.nap.edu/openbook.php?record_id=10863&page=30#. Last
591 accessed December 2010.
- 592 2. Reducing Errors in Healthcare: Translating Research Into Practice (2000). The Agency
593 for Healthcare Research and Quality (AHRQ); 2000. Available at
594 <http://www.ahrq.gov/qual/errors.htm>. Last accessed December 2010.
- 595 3. Ibid.
- 596 4. National Quality Forum (NQF), *The ABCs of Measurement*, Washington, DC: NQF;
597 2010.
- 598 5. National Quality Forum (NQF), *Serious Reportable Events in Healthcare*, Washington,
599 DC: NQF; 2002.
- 600 6. National Quality Forum (NQF), *Safe Practices for Better Healthcare*, Washington, DC:
601 NQF; 2003.
- 602 7. National Quality Forum (NQF), National Priorities Partnership, Washington, DC: NQF.
603 Available at www.nationalprioritiespartnership.org. Last accessed December 2010.
- 604 8. National Quality Forum (NQF), Patient Safety Measures, Washington, DC: NQF.
605 http://www.qualityforum.org/projects/patient_safety_measures.aspx. Last accessed
606 December 2010.
- 607 9. National Quality Forum (NQF). Measure Evaluation Criteria. Washington, DC: NQF;
608 2008. Available at http://www.qualityforum.org/docs/measure_evaluation_criteria.aspx.
609 Last accessed December 2010.
- 610 10. Paired or grouped measures refer to two or more measures grouped together for the
611 purpose of public reporting. The measures maintain separate scores.
- 612 11. Scott II, RD. Centers for Disease Control and Prevention (CDC). The Direct Medical
613 Costs of Healthcare-Associated Infections in U.S. Hospitals and the Benefits of
614 Prevention. CDC: 2010. Available at
615 http://www.cdc.gov/ncidod/dhqp/pdf/Scott_CostPaper.pdf. Last accessed December
616 2010.

NQF REVIEW DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER comments due February 9, 2011, 6:00 PM ET; PUBLIC comments due February 2, 2011 by 6:00 PM ET

NATIONAL QUALITY FORUM

617 12. Harmonization refers to the standardization of specifications for similar measures on the
618 same topic (e.g., *influenza immunization* of patients in hospitals or nursing homes), or related
619 measures for the same target population (e.g., eye exam and HbA1c for *patients with*
620 *diabetes*), or definitions applicable to many measures (e.g., age designation for children) so
621 that they are uniform or compatible, unless differences are dictated by the evidence. The
622 dimensions of harmonization can include numerator, denominator, exclusions, and data
623 source and collection instructions. The extent of harmonization depends on the relationship
624 of the measures, the evidence for the specific measure focus, and differences in data sources.

NQF REVIEW DRAFT—DO NOT CITE OR QUOTE

NQF MEMBER comments due February 9, 2011, 6:00 PM ET; PUBLIC comments due February 2, 2011 by 6:00 PM ET

NATIONAL VOLUNTARY CONSENSUS STANDARDS FOR PATIENT SAFETY MEASURES:
A CONSENSUS REPORT
APPENDIX A: MEASURE SPECIFICATIONS

The following table presents the detailed specifications for the National Quality Forum (NQF)-endorsed® *National Voluntary Consensus Standards for Patient Safety*. All information presented has been derived directly from measure sources/ developers without modifications or alteration (except when the measure developer agreed to such modifications during the NQF Consensus Development Process) and is current as of April 6, 2011. All NQF-endorsed voluntary consensus standards are open source, meaning they are fully accessible and disclosed. Measures were developed by the ©AAAHC Institute for Quality Improvement, American College of Radiology (ACR) and the University of California San Francisco.

Measure Numbers	Measure Title	Measure Steward	Measure Description	Numerator	Denominator	Exclusions Adjustments	Data Source	Level of Analysis
PSM-014-10 * Paired with measures PSM-015-10 and PSM-016-10	Colonoscope Processing Personnel Instruction	©AAAHC Institute for Quality Improvement	Percentage of all colonoscope reprocessing personnel at Ambulatory Surgery Centers and Office-Based Practices who receive device-specific instructions at least annually, as well as whenever any changes are made in colonoscope equipment or in manufacturers' recommendations, to ensure proper colonoscope reprocessing	Colonoscope processing personnel at Ambulatory Surgery Centers and Office-Based Practices who receive device-specific reprocessing instructions at least annually, as well as whenever any changes are made in colonoscope equipment or in manufacturers' recommendations, to ensure appropriate cleaning and high-level disinfection or sterilization	All colonoscope reprocessing personnel at Ambulatory Surgery Centers and Office-Based Practices	None.	Survey: Provider	Facility/ Agency; Can be measured at all levels

NATIONAL VOLUNTARY CONSENSUS STANDARDS FOR PATIENT SAFETY MEASURES:
A CONSENSUS REPORT
APPENDIX A: MEASURE SPECIFICATIONS

Measure Numbers	Measure Title	Measure Steward	Measure Description	Numerator	Denominator	Exclusions Adjustments	Data Source	Level of Analysis
PSM-015-10 * Paired with measures PSM-014-10 and PSM-016-10	Colonoscope Processing Currency	©AAAHC Institute for Quality Improvement	Whether or not Ambulatory Surgery Centers and Office-Based Practices performing colonoscopies review national device-specific reprocessing guidelines and manufacturers' recommendations for reprocessing colonoscopes at least annually (every 12 months), as well as whenever any changes are made in colonoscope equipment or in manufacturers' recommendations, and revise their policies and procedures to incorporate any changes that have occurred	Ambulatory Surgery Centers and Office-Based Practices performing colonoscopies that review national device-specific reprocessing guidelines and manufacturers' recommendations for reprocessing colonoscopes at least annually (every 12 months), as well as whenever any changes are made in colonoscope equipment or in manufacturers' recommendations, and revise their policies and procedures to incorporate any changes that have occurred	All Ambulatory Surgery Centers and Office-Based Practices performing colonoscopies	None	Survey: Provider	Facility/ Agency; Can be measured at all levels

NATIONAL VOLUNTARY CONSENSUS STANDARDS FOR PATIENT SAFETY MEASURES:
A CONSENSUS REPORT
APPENDIX A: MEASURE SPECIFICATIONS

Measure Numbers	Measure Title	Measure Steward	Measure Description	Numerator	Denominator	Exclusions Adjustments	Data Source	Level of Analysis
PSM-016-10 * Paired with measures PSM-014-10 and PSM-015-10	Colonoscope Processing Competency	©AAAHC Institute for Quality Improvement	Percentage of all colonoscope reprocessing personnel at Ambulatory Surgery Centers and Office-Based Practices who are documented to be competent at reprocessing colonoscopes on initial assignment and at least annually thereafter, as well as whenever any changes are made in colonoscope equipment or in manufacturers' recommendations.	Colonoscope reprocessing personnel who are documented to be competent at reprocessing colonoscopes on initial assignment and at least annually thereafter, as well as whenever any changes are made in colonoscope equipment or in manufacturers' recommendations	All colonoscope reprocessing personnel at Ambulatory Surgery Centers or Office-Based Practices	None	Management data; Survey: Provider	Facility/ Agency

NATIONAL VOLUNTARY CONSENSUS STANDARDS FOR PATIENT SAFETY MEASURES:
A CONSENSUS REPORT
APPENDIX A: MEASURE SPECIFICATIONS

Measure Numbers	Measure Title	Measure Steward	Measure Description	Numerator	Denominator	Exclusions Adjustments	Data Source	Level of Analysis
PSM-043-10	Participation in a Systematic National Dose Index Registry	©American College of Radiology	Participation in a multi-center, standardized data collection and feedback program that will establish national dose index benchmarks for designated examinations. The registry will eventually provide a comparison of practice or facility dose indices such as CTDIvol and DLP for specified examinations relative to national and regional benchmarks. Data is captured electronically from the images of CT examinations using Digital Imaging and Communications in Medicine (DICOM) standards and the Integrating the Healthcare Enterprise (IHE) Radiation Exposure Monitoring (REM) profile.	Participation in a systematic national dose index registry.	The measure does not have a numerator/denominator. It is strictly an attestation – Yes or No.		Registry data; Documentation of original self-assessment	Clinicians: Group; Facility/ Agency; Integrated delivery system; Multi-site/corporate chain; Population: national; Population: regional/network; Can be measured at all levels; Population: states; Population: counties or cities

NATIONAL VOLUNTARY CONSENSUS STANDARDS FOR PATIENT SAFETY MEASURES:
A CONSENSUS REPORT
APPENDIX A: MEASURE SPECIFICATIONS

Measure Numbers	Measure Title	Measure Steward	Measure Description	Numerator	Denominator	Exclusions Adjustments	Data Source	Level of Analysis
PSM-044-10	Radiation Dose of Computed Tomography (CT)	University of California San Francisco	The measure has two components. Part A is an outcome measure; Part B is a process measure. Both would work together towards improving quality and allowing hospitals and imaging facilities to conduct ongoing quality improvement. Part A: radiation dose associated with computed tomography (CT) examinations of the head, neck, chest, abdomen/pelvis and lumbar spine, obtained in children and adults. Part B: The proportion of CT examinations where a measure of dose is included in the final medical report	Part A: Radiation Dose, quantified using DLP, CTDIvol; within anatomic area, age, and machine-type strata Part B: The proportion of CT scans of one of the included anatomic areas with a measure of radiation dose reported in the final approved report. (The reported measure can be DLP, CTDIvol or Effective Dose.)	Part A and Part B: Consecutive sample of CTs conducted in the head, chest, abdomen/pelvis and lumbar spine.	Part A and Part B. CT examinations conducted in anatomic areas not included above (such as CTs of the extremities). Note: among examination types not to be included in adults are "limited abdomen" or "limited pelvis" studies. In children, all abdomen and pelvis CT scans are included in the abdomen/pelvis category.	Electronic Health/Medical Record	Facility/Agency



Patient Safety Measures Medication Safety TAP

David Nau, PhD, RPh, CPHQ (Chair)

Pharmacy Quality Alliance, Lexington, KY

Eric Alper, MD, FACP, FHM

UMass Memorial Medical Center, Worcester, MA

Clifton Bingham, MD

Johns Hopkins University, Baltimore, MD

Kris Kowdley, MD, FACP, FACG, FA

Virginia Mason Medical Center, Seattle, WA

Jessica Maack-Rangel, RN, MS

Texas Health Resources, Arlington, TX

Stephen Muething, MD

Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Daniel Solomon, MD

Brigham and Women's Hospital, Boston, MA

Peter Wong, MBA, MS, PhD, RPh

Sisters of Charity of Leavenworth Health System, Lenexa, KS

Patient Safety Measures Perinatal TAP

Steven Clark, MD (Chair)

Hospital Corporation of America, Nashville, TN

Alan Fleischman, MD

March of Dimes - National Office, White Plains, NY



Diana Jolles, CNM, MS

California Maternal Quality Care Collaborative, Stanford, CA

Elliott Main, MD

Association of Women's Health, Obstetric and Neonatal Nurses, Washington, DC

Karen Peddicord, PhD

Massachusetts General Hospital, Boston, MA

Laura Riley, MD

Childbirth Connection, New York, NY

Patient Safety Measures Steering Committee

William Conway, MD (Co-Chair)

Henry Ford Health System, Detroit, MI

Lisa Thiemann, CRNA, MNA (Co-Chair)

American Association of Nurse Anesthetists, Park Ridge, IL

Jan Allison, RN, CHSP

Surgical Care Affiliates, Washington, OK

Robert Bunting, MSA, CPHRM, CPHQ, MT

WellPoint, Columbus, GA

Darrell Campbell, MD

University of Michigan Hospitals & Health Centers, Ann Arbor, MI

Steven Clark, MD

Hospital Corporation of America, Nashville, TN

Cynthia de Luise, MPH, PhD

Pfizer, New York, NY

Ellis Diamond, MD

American Academy of Neurology, Carlsbad, CA



Donald Kennerly, MD, PhD

Baylor Health Care System, Dallas, TX

Clifton Knight, MD

Community Hospital of Indiana, Inc., Indianapolis, IN

Kris Kowdley, MD, FACP, FACG, FA

Virginia Mason Medical Center, Seattle, WA

Stephen Lawless, MD, MBA

Nemours Foundation, Wilmington, DE

Alan Levine

Consumers Advancing Patient Safety, Washington, DC

Stephen Muething, MD

Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Janet Nagamine, MD, RN

Society of Hospital Medicine, Aptos, CA

Paul Nagy, PhD

University of Maryland School of Medicine, Baltimore, MD

David Nau, PhD, RPh, CPHQ

Pharmacy Quality Alliance, Lexington, KY

Paul Sierzenski, MD

Christiana Care Health System, Bear, DE

Daniel Solomon, MD

Brigham and Women's Hospital, Boston, MA

Iona Thraen, MSW

Utah Department of Health, Salt Lake City, Utah

David Turner, MD, PhD, MPH

Monsanto, Saint Louis, MO



NQF Staff

Peter Angood, MD

Senior Advisor

Heidi Bossley, MSN, MBA

Managing Director

Helen Burstin, MD

Senior Vice President

Andrew Lyzenga, MPP

Project Manager

Elisa Munthali, MPH

Project Manager

Lindsey Tighe, MPH

Research Analyst

Jessica Weber, MPH

Research Analyst

NQF-endorsed® Patient Safety Measures

Table of Contents

Measure# 0019: Documentation of medication list in the outpatient record	3
Measure# 0020: Documentation of allergies and adverse reactions in the outpatient record	3
Measure# 0021: Therapeutic monitoring: Annual monitoring for patients on persistent medications	3
Measure# 0022: Drugs to be avoided in the elderly: a. Patients who receive at least one drug to be avoided, b. Patients who receive at least two different drugs to be avoided.	4
Measure# 0035: Fall risk management in older adults: a. Discussing fall risk, b.Managing fall risk	4
Measure# 0101: Falls: Screening for Fall Risk	5
Measure# 0138: Urinary catheter-associated urinary tract infection for intensive care unit (ICU) patients	6
Measure# 0139: Central line catheter-associated blood stream infection rate for ICU and high-risk nursery (HRN) patients	6
Measure# 0140: Ventilator-associated pneumonia for ICU and high-risk nursery (HRN) patients	6
Measure# 0141: Patient Fall Rate	7
Measure# 0184: Residents who have a catheter in the bladder at any time during the 14-day assessment period. (risk adjusted)	8
Measure# 0187: Recently hospitalized residents with pressure ulcers (risk adjusted)	9
Measure# 0193: Residents who were physically restrained daily during the 7-day assessment period	10
Measure# 0196: Residents with a urinary tract infection	10
Measure# 0198: High-risk residents with pressure ulcers	11
Measure# 0199: Average-risk residents with pressure ulcers	11
Measure# 0201: Pressure ulcer prevalence	12
Measure# 0202: Falls with injury	13
Measure# 0203: Restraint prevalence (vest and limb only)	14
Measure# 0239: Venous Thromboembolism (VTE) Prophylaxis	15
Measure# 0263: Patient Burn	15
Measure# 0265: Hospital Transfer/Admission	15
Measure# 0266: Patient Fall	16
Measure# 0267: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant	16
Measure# 0298: Central Line Bundle Compliance	16
Measure# 0299: Surgical Site Infection Rate	17
Measure# 0301: Surgery patients with appropriate hair removal	18
Measure# 0302: Ventilator Bundle	19
Measure# 0337: Decubitus Ulcer (PDI 2)	19
Measure# 0345: Accidental Puncture or Laceration (PSI 15)	20
Measure# 0346: Iatrogenic Pneumothorax (PSI 6) (risk adjusted)	20
Measure# 0347: Death in Low Mortality DRGs (PSI 2)	21
Measure# 0348: Iatrogenic Pneumothorax in Non-Neonates (PDI 5) (risk adjusted)	21
Measure# 0349: Transfusion Reaction (PSI 16)	22

Measure# 0350: Transfusion Reaction (PDI 13)..... 22
Measure# 0352: Failure to Rescue In-Hospital Mortality (risk adjusted) 23
Measure# 0353: Failure to Rescue 30-Day Mortality (risk adjusted) 24
Measure# 0362: Foreign Body left after procedure (PDI 3)..... 24
Measure# 0363: Foreign Body Left in During Procedure (PSI 5)..... 25
Measure# 0371: Venous Thromboembolism (VTE) Prophylaxis 25
Measure# 0589: Rheumatoid Arthritis New DMARD Baseline Serum Creatinine 26

Measure# 0019: Documentation of medication list in the outpatient record	
Steward	Centers for Medicare & Medicaid Services, National Committee for Quality Assurance
Description	Percentage of patients having a medication list in the medical record.
Numerator	Patients with a medication list in their medical record
Denominator	All patients who were continuously enrolled during the measurement year.
Exclusions	
Risk Adjustment	
Data Source	Paper Medical Record
Level	Individual clinician (physician, nurse)
Setting	Ambulatory Care (office/clinic)
Measure# 0020: Documentation of allergies and adverse reactions in the outpatient record	
Steward	Centers for Medicare & Medicaid Services, National Committee for Quality Assurance
Description	Percentage of patients having documentation of allergies and adverse reactions in the medical record.
Numerator	Patients with allergy and adverse reaction status present in medical record
Denominator	All patients who were continuously enrolled during the measurement year.
Exclusions	
Risk Adjustment	
Data Source	Paper Medical Record
Level	Individual clinician (physician, nurse)
Setting	Ambulatory Care (office/clinic)
Measure# 0021: Therapeutic monitoring: Annual monitoring for patients on persistent medications	
Steward	National Committee for Quality Assurance
Description	Percentage of patients 18 years and older who received at least 180-day supply of medication therapy for the selected therapeutic agent and who received annual monitoring for the therapeutic agent. Percentage of patients on ACE inhibitors or ARBs with a
Numerator	a: The number of patients with at least one serum potassium and either a serum creatinine or a blood urea nitrogen therapeutic monitoring test in the measurement year. b: The number of patients with at least one serum potassium and either a serum creatinine or a blood urea nitrogen therapeutic monitoring test in the measurement year. c: The number of patients with at least one serum potassium and either a serum creatinine or a blood urea nitrogen therapeutic monitoring test in the measurement year. Note: The two tests do not need to occur on the same service date, only within the measurement year. d: The number of patients with at least one drug serum concentration level monitoring test for the prescribed drug in the measurement year. If a patient received only one type of anticonvulsant, the drug serum concentration level test must be for the specific drug taken as a persistent medication. If a patient persistently received multiple types of anticonvulsants, each anticonvulsant medication and drug monitoring test combination is counted as a unique event (i.e., a patient on both phenytoin and valproic acid with at least a 180-days supply for each drug in the measurement year must separately show evidence of receiving drug serum concentration tests for each drug to be considered numerator-compliant for each drug). e: The number of patients with both an ALT and an AST liver enzyme test in the measurement year. A hepatic function panel (which includes both a ALT and AST) also counts as numerator compliant. F: Sum of the five numerators (a-e)
Denominator	a: The number of patients ages 18 years and older who received at least a 180-days supply of ACE inhibitors or ARBs, including any combination products during the measurement year. b: The number of patients ages 18 years and older who received at least a 180-days supply of digoxin, including any combination products, during the measurement year. c: The number of patients ages 18 years and older who received at least a 180-days supply of a diuretic, including any combination products, during the measurement year

	<p>d: The number of patients in the denominator who received at least a 180-days supply for any anticonvulsant for phenytoin, phenobarbital, valproic acid or carbamazepine during the measurement year. Each patient-drug combination is considered a unique event.</p> <p>e: The number of patients in the denominator who received at least a 180-days supply for any statin (HMG CoA Reductase Inhibitors), including any combination product, during the measurement year.</p> <p>F: Sum of the five denominators (a-e)</p>
Exclusions	<p>a. Exclude patients from each rate denominator with a hospitalization in the measurement year. These patients may have received a monitoring event during the hospitalization which may not be captured. Hospitalizations can be identified using either codes for inpatient discharges or non acute care or through the medical record.</p> <p>B. Exclude patients from each rate denominator with a hospitalization in the measurement year. These patients may have received a monitoring event during the hospitalization which may not be captured. Hospitalizations can be identified using either codes for inpatient discharges or non acute care or through medical records.</p> <p>C. Exclude patients from each rate denominator with a hospitalization in the measurement year. These patients may have received a monitoring event during the hospitalization which may not be captured. Hospitalizations can be identified using either codes for inpatient discharges or non acute care or medical records.</p> <p>D. Exclude patients from each rate denominator with a hospitalization in the measurement year. These patients may have received a monitoring event during the hospitalization which may not be captured. Hospitalizations can be identified using either codes for inpatient discharges or non acute care.</p> <p>E. Exclude patients from each rate denominator with a hospitalization in the measurement year. These patients may have received a monitoring event during the hospitalization which may not be captured. Hospitalizations can be identified using either codes for inpatient discharges or non acute care or medical records.</p>
Risk Adjustment	
Data Source	Electronic Claims
Level	Individual clinician (physician, nurse)
Setting	Ambulatory Care (office/clinic)
Measure# 0022: Drugs to be avoided in the elderly: a. Patients who receive at least one drug to be avoided, b. Patients who receive at least two different drugs to be avoided.	
Steward	National Committee for Quality Assurance
Description	<p>Percentage of patients ages 65 years and older who received at least one drug to be avoided in the elderly in the measurement year.</p> <p>Percentage of patients 65 years of age and older who received at least two different drugs to be avoided in the elderly in</p>
Numerator	<p>a: at least one prescription for any drug to be avoided in the elderly in the measurement year.</p> <p>b: At least two different drugs to be avoided in the elderly in the measurement year.</p>
Denominator	All patients ages 65 years and older as of December 31 of the measurement year.
Exclusions	
Risk Adjustment	
Data Source	Electronic Claims
Level	Individual clinician (physician, nurse)
Setting	Ambulatory Care (office/clinic)
Measure# 0035: Fall risk management in older adults: a. Discussing fall risk, b.Managing fall risk	
Steward	National Committee for Quality Assurance
Description	<p>Percentage of patients aged 75 and older who reported that their doctor or other health provider talked with them about falling or problems with balance or walking</p> <p>Percentage of patients aged 75 and older who reported that their doctor or other health pr</p>
Numerator	a- Discussing Fall Risk: The number of patients in the denominator a who responded “yes” to the question, “A fall is when your body goes to the ground without being pushed. In the past 12 months, did your doctor or other health provider talk with you about falling or problems with balance or walking?”

	b- Managing Fall Risk: The number of patients in the denominatorb who responded “yes” to the question, “Has your doctor or other health provider done these or anything else to help prevent falls or treat problems with balance or walking? “
Denominator	a- Discussing Fall Risk: All patients 75 years and older as of December 31 of the measurement year, AND patients 65 years to 74 years as of December 31 of the measurement year who responded “yes” to either of the questions, “Did you fall in the past 12 months?” - - Q2 OR “yes” to the question, “In the past 12 months, have you had problems with balance or walking?” - - Q3 and who indicated they were seen by a provider during the measurement year. b- Managing Fall Risk: Patients 65 years and older as of December 31 of the measurement year who responded “yes” to either of the questions, “Did you fall in the past 12 months?” - - Q2 OR “yes” to the question, “In the past 12 months, have you had problems with balance or walking?” - - Q3 and who indicated they were seen by a provider during the measurement year.
Exclusions	
Risk Adjustment	
Data Source	Electronic Claims
Level	Individual clinician (physician, nurse)
Setting	Ambulatory Care (office/clinic)
Measure# 0101: Falls: Screening for Fall Risk	
Steward	American Geriatrics Society, American Medical Association, National Committee for Quality Assurance, American Medical Association - Physician Consortium for Performance Improvement
Description	Percentage of patients aged 65 years and older who were screened for fall risk (2 or more falls in the past year or any fall with injury in the past year) at least once within 12 months
Numerator	Patients who were screened for future fall risk (patients are considered at risk for future falls if they have had 2 or more falls in the past year or any fall with injury in the past year) at least once within 12 months Definition: A fall is defined as a sudden, unintentional change in position causing an individual to land at a lower level, on an object, the floor, or the ground, other than as a consequence of sudden onset of paralysis, epileptic seizure, or overwhelming external force (Tinetti).
Denominator	All patients aged 65 years and older
Exclusions	Documentation of medical reason(s) for not screening for future fall risk (e.g., patient is not ambulatory) Exclude patients for whom patient was not an eligible candidate for fall risk screening by reason of medical exclusion.
Risk Adjustment	
Data Source	Electronic Claims
Level	Individual clinician (physician, nurse)
Setting	Ambulatory Care (office/clinic)

Measure# 0138: Urinary catheter-associated urinary tract infection for intensive care unit (ICU) patients	
Steward	Centers for Disease Control and Prevention
Description	Percentage of intensive care unit patients with urinary catheter-associated urinary tract infections
Numerator	Number of indwelling urinary catheter-associated UTIs (defined by CDC case definitions of symptomatic UTI or asymptomatic bacteriuria, excludes other infections of the urinary tract) x 1,000
Denominator	Number of indwelling urinary catheter days for ICU patients ?Reported by type of ICU (coronary, cardiothoracic, medical, medical-surgical (major teaching and all others), neurosurgical, pediatric, surgical, trauma, burn, and respiratory)
Exclusions	
Risk Adjustment	Comparisons are made among ICUs of similar type: Coronary, Cardiothoracic, medical, medical-surgical (major teaching and all others), Neurosurgical, Pediatric, Surgical, Trauma, Burn and Respiratory
Data Source	Electronic Clinical Database
Level	Facility (e.g., hospital, nursing home)
Setting	Hospital
Measure# 0139: Central line catheter-associated blood stream infection rate for ICU and high-risk nursery (HRN) patients	
Steward	Centers for Disease Control and Prevention
Description	Percentage of ICU and high-risk nursery patients, who over a certain amount of days acquired a central line catheter-associated blood stream infections over a specified amount of line-days
Numerator	Number of central line-associated blood stream infections (laboratory-confirmed bloodstream infection or clinical sepsis) x 1,000 Number of umbilical and central line-associated blood stream infections (laboratory-confirmed bloodstream infection or clinical sepsis) x 1,000
Denominator	Number of central line-days for ICU patients. Reported by type of ICU (coronary, cardiothoracic, medical, medical-surgical (major teaching and all others), neurosurgical, pediatric, surgical, trauma, burn, and respiratory) Number of central-line days for HRN patients ?Reported for HRNs by birth weight category (<1,000, 1,001-1,500, 1,501-2,500, and >2,500g)
Exclusions	
Risk Adjustment	The measure is reported stratified by ICU-type, and the denominator as stated per 1,000 line days adjusts for the increased risk over time after a central line is inserted
Data Source	Electronic Clinical Database
Level	Facility (e.g., hospital, nursing home)
Setting	Hospital
Measure# 0140: Ventilator-associated pneumonia for ICU and high-risk nursery (HRN) patients	
Steward	Centers for Disease Control and Prevention
Description	Percentage of ICU and HRN patients who over a certain amount of days have ventilator-associated pneumonia
Numerator	Number of ventilator-associated pneumonias x 1,000
Denominator	Number of ventilator-days for ICU patients: Reported by type of ICU (coronary, cardiothoracic, medical, medical-surgical (major teaching and all others), neurosurgical, pediatric, surgical, trauma, burn, and respiratory) Number of ventilator days for HRN patients: Reported for HRNs by birth weight category (<1,000, 1,001-1,500, 1,501-2,500, and >2,500g)
Exclusions	
Risk Adjustment	Risk Adjustment: This measure of ventilator-associated pneumonias per ventilator days is adjusted for the major risk factor, which is use of catheters, as well as length of stay.
Data Source	Electronic Clinical Database
Level	Facility (e.g., hospital, nursing home)
Setting	Hospital

Measure# 0141: Patient Fall Rate	
Steward	American Nurses Association
Description	All documented falls, with or without injury, experienced by patients on an eligible unit in a calendar quarter.
Numerator	<p>Total number of patient falls (with or without injury to the patient and whether or not assisted by a staff member) by hospital Unit during the month X 1000.</p> <p>Time window: Month</p> <p>Fall Definition: A patient fall is an unplanned descent to the floor (or extension of the floor, e.g., trash can or other equipment) with or without injury to the patient, and occurs on an eligible reporting nursing unit. All types of falls are to be included whether they result from physiological reasons (fainting) or environmental reasons (slippery floor). Include assisted falls – when a staff member attempts to minimize the impact of the fall.</p> <p>Included Populations:</p> <ul style="list-style-type: none"> • Patient falls occurring while on an eligible reporting unit • Assisted falls • Repeat falls <p>Excluded Populations:</p> <p>Falls by:</p> <ul style="list-style-type: none"> • Visitors • Students • Staff members • Falls by patients from eligible reporting unit, however patient was not on unit at time of fall (e.g., patients falls in radiology department) • Falls on other unit types (e.g., pediatric, psychiatric, obstetrical, rehab, etc) <p>Data Elements: Collected at a patient level</p> <ul style="list-style-type: none"> • Month • Year • Age • Gender • Event Type (fall, assisted fall, repeat fall) • Type of Unit • Fall Risk Assessment • Fall Risk • Fall Prevention Protocol
Denominator	<p>Patient days by hospital Unit during the calendar month</p> <p>Time window: Calendar Month</p> <p>Included Populations:</p> <ul style="list-style-type: none"> • Inpatients, short stay patients, observation patients and same day surgery patients who receive care on eligible in-patient units for all or part of a day. • Adult critical care, step-down, medical, surgical, medical-surgical combined units. • Any age patient on an eligible reporting unit is included in the patient day count. <p>Four (4) Patient Days reporting methods are recognized:</p> <ul style="list-style-type: none"> • Method 1-Midnight Census This is adequate for units that have all in-patient admissions. It is the least accurate method for units that have both in-patient and short stay patients. The daily number should be summed for every day in the month. • Method 2-Midnight Census + Patient Days from Actual Hours for Short Stay Patients This is an accurate method for units that have both in-patients and short stay patients. The short stay “days” should be reported separately from midnight census and will be summed to obtain patient days. The total daily hours for short stay patients should be summed for the month and divided by 24. • Method 3-from Average Hours for Short Stay Patients This method has been eliminated from the list of acceptable reporting methods. • Method 4-Patient Days from Actual Hours This is the most accurate method. An increasing number of facilities have accounting systems that track the actual time spent in the facility by each patient. Sum actual hours for all patients, whether in-patient or short stay, and divide by 24. • Method 5-Patient Days from Multiple Census Reports Some facilities collect censuses multiple times per day (e.g., every 4 hours or each shift). This method is more

	<p>accurate than the Midnight Census, but not as accurate as Midnight Census + Actual Short Stay hours, or as Actual Patient Hours. A sum of the daily average censuses can be calculated to determine patient days for the month on the unit.</p> <p>For all patient day reporting methods, it is recommended that hospitals consistently use the same method for a reporting unit over time. However, units with short stay patients should transition either to Method 2 or Method 4 when it becomes feasible.</p> <p>Data Elements:</p> <ul style="list-style-type: none"> • Month • Year • Patient Days Reporting method which includes midnight census and short stay patient days • Type of Unit
Exclusions	Excluded Populations: Other unit types (e.g., pediatric, psychiatric, obstetrical, rehab, etc)
Risk Adjustment	Stratification by facility size and unit; documentation of falls risk assessment on admission; fall protocol implementation; level of patient activity prior to fall
Data Source	Paper Medical Record, Electronic Health/Medical Record, Electronic source – Other, Other
Level	Group of clinicians (facility, dept/unit, group)
Setting	Hospital
Measure# 0184: Residents who have a catheter in the bladder at any time during the 14-day assessment period. (risk adjusted)	
Steward	Centers for Medicare & Medicaid Services
Description	Percentage of residents with a valid target assessment who have a catheter in the bladder at any time during the 14-day assessment period.
Numerator	Indwelling catheter on target assessment (H3d=checked)
Denominator	All residents with a valid target assessment.
Exclusions	<p>Exclusions:</p> <p>Residents satisfying any of the following conditions:</p> <ol style="list-style-type: none"> 1. The target assessment is an admission (AA8a = 01). 2. H3d is missing on the target assessment. 3. The resident is in a facility with a Chronic Care Admission Sample size of 0 (i.e., there are no admission assessments with AA8a = 01 in the facility over the previous 12 months). <p>Covariates:</p> <ol style="list-style-type: none"> 1. Indicator of bowel incontinence on the prior assessment: Covariate =1 if H1a =4. Covariate =0 if H1a = 0,1,2, or 3. 2. Indicator of pressure ulcers on the prior assessment: Covariate =1 if M2a = 3 or 4. Covariate =0 if M2a = 0.
Risk Adjustment	<p>Risk adjustment: For each of the five risk-adjusted QMs, a resident- level logistic regression was estimated. Data came from the chronic or post acute residents in the 20 percent random samples of all facilities for a one-year period, Quarter 4 of 2001 (Q4 2001) through Quarter 3 of 2002 (Q3 2002). The resident- level observed QM score was the dependent variable. The predictor variables were one or more resident- level covariates associated with the QM. More information is available here: http://www.cms.hhs.gov/NursingHomeQualityInits/Downloads/NHQIQMUsersManual.pdf</p>
Data Source	Standardized clinical instrument
Level	Facility (e.g., hospital, nursing home)
Setting	Nursing home/ Skilled Nursing Facility (SNF)

Measure# 0187: Recently hospitalized residents with pressure ulcers (risk adjusted)	
Steward	Centers for Medicare & Medicaid Services
Description	Recently hospitalized residents with pressure ulcers
Numerator	SNF PPS Patients who satisfy either of the following conditions: 1. On the SNF PPS 5-day assessment, the patient had no pressure ulcers (M2a[t-1]=0) AND, on the SNF PPS 14-day assessment, the patient has at least a stage 1 pressure ulcer (M2a[t]=1,2,3, or 4). 2. On the SNF PPS 5-day assessment, the patient had a pressure ulcer (M2a[t-1] = 1,2,3, or 4) AND on the SNF PPS 14-day assessment, pressure ulcers worsened or failed to improve (M2a[t]>=M2a[t-1]).
Denominator	All patients with a valid SNF PPS 14-day assessment (AA8b=7) AND a valid preceding SNF PPS 5-day assessment (AA8b=1).
Exclusions	Exclusions: Patients satisfying the following condition: 1. M2a is missing on the 14-day assessment [t] 2. M2a is missing on the 5-day assessment [t-1] and M2a shows presence of pressure ulcers on the 14-day assessment (M2a=1,2,3, or 4). 3. The Patient is in a facility with a Post Acute Care Admission Sample size of 0 (i.e., there are no SNF PPS 5-day assessments with AA8b =1 in the facility over the previous 12 months) Covariates: 1. Indicator of history of unresolved pressure ulcer on the SNF PPS 5-day assessment. Covariate =1 if M3 =1. Covariate =0 if M3 =0. 2. Indicator of requiring limited or more assistance in bed mobility on the SNF PPS 5-day assessment: Covariate = 1 if G1a(A) = 2,3,4, or 8. Covariate = 0 if G1a(A) =0 or 1. 3. Indicator of bowel incontinence at least one/week on the SNF PPS 5-day assessment: Covariate =1 if H1a 2,3, or 4. Covariate =0 if H1a = 0 or 1. 4. Indicator of diabetes or peripheral vascular disease on the SNF PPS 5-day assessment: Covariate =1 if I1a checked (value 1) or I1j checked (value 1). Covariate =0 if I1a not checked (value 0) and I1j not checked (value 0). 5. Indicator of Low Body Mass Index (BMI) on the SNF PPS 5-day assessment: Covariate = 1 if BMI >=12 and <=19. Covariate = 0 if BMI > 19 and <= 40. Where: BMI = weight(kg)/height ² (m ²) = ((K2b*0.45)/(((K2a)*.0254) ²)) (Note: An implausible BMI value <12 or >40 will be treated as a missing value on this covariate.
Risk Adjustment	Risk adjustment: For each of the five risk-adjusted QMs, a resident- level logistic regression was estimated. Data came from the chronic or post acute residents in the 20 percent random samples of all facilities for a one-year period, Quarter 4 of 2001 (Q4 2001) through Quarter 3 of 2002 (Q3 2002). The resident- level observed QM score was the dependent variable. The predictor variables were one or more resident- level covariates associated with the QM. More information is available here: http://www.cms.hhs.gov/NursingHomeQualityInits/Downloads/NHQIQMUsersManual.pdf
Data Source	Standardized clinical instrument
Level	Facility (e.g., hospital, nursing home)
Setting	Nursing home/ Skilled Nursing Facility (SNF)

Measure# 0193: Residents who were physically restrained daily during the 7-day assessment period	
Steward	Centers for Medicare & Medicaid Services
Description	Percentage of residents on most recent assessments who were physically restrained daily during the 7-day assessment period
Numerator	Residents who were physically restrained daily on most recent assessment.
Denominator	All residents on most recent assessments.
Exclusions	
Risk Adjustment	
Data Source	Standardized clinical instrument
Level	Facility (e.g., hospital, nursing home)
Setting	Nursing home/ Skilled Nursing Facility (SNF)
Measure# 0196: Residents with a urinary tract infection	
Steward	Centers for Medicare & Medicaid Services
Description	Percentage of residents on most recent assessment with a urinary tract infection
Numerator	Residents with urinary tract infection on target assessment. (I2j = checked)
Denominator	All residents with a valid target assessment.
Exclusions	Exclusions: Residents satisfying any of the following conditions: 1. The target assessment is an admission (AA8a = 01) assessment. 2. I2j is missing on the target assessment.
Risk Adjustment	
Data Source	Standardized clinical instrument
Level	Facility (e.g., hospital, nursing home)
Setting	Nursing home/ Skilled Nursing Facility (SNF)

Measure# 0198: High-risk residents with pressure ulcers	
Steward	Centers for Medicare & Medicaid Services
Description	Percentage of residents with a valid target assessment and one of the following inclusion criteria: 1. Impaired in mobility or transfer on the target assessment 2. Comatose on the target assessment 3. Suffer malnutrition on the target assessment who
Numerator	Residents with pressure ulcers (Stage 1-4) on target assessment (M2a >0 OR I3a-3 =707.0)
Denominator	All residents with a valid target assessment and any one of the following inclusion criteria 1. Impaired in mobility or transfer on the target assessment as indicated by G1a(A) = 3, 4, or 8 OR G1b(A) = 3, 4, or 8. 2. Comatose on the target assessment as indicated by B1 = 1. 3. Suffer malnutrition on the target assessment as indicated by I3a through I3e = 260, 261, 262, 263.0, 263.1, 263.2, 263.8, or 263.9.
Exclusions	Exclusions for both measures: Residents satisfying any of the following conditions are excluded from all risk groups (high and low, high, and low) – this is 1, with 1, 2, and 3 below being 1.1, 1.2, and 1.3: 1. The target assessment is an admission (AA8a = 01) assessment. 2. The QM did not trigger (resident is not included in the QM numerator) AND the value of M2a is missing on the target assessment. 3. The resident is in a facility with a Chronic Care Admission Sample size of 0 (i.e., there are no admission assessments with AA8a = 01 in the facility over the previous 12 months). 4. The resident does not qualify as high-risk AND the value of G1a(A) or G1b(A) is missing on the target assessment. 5. The resident does not qualify as high-risk AND the Value of B1 is missing on the target assessment.
Risk Adjustment	None.
Data Source	Standardized clinical instrument
Level	Facility (e.g., hospital, nursing home)
Setting	Nursing home/ Skilled Nursing Facility (SNF)
Measure# 0199: Average-risk residents with pressure ulcers	
Steward	Centers for Medicare & Medicaid Services
Description	Percentage of residents with a valid target assessment and not qualifying as high risk with pressure ulcers
Numerator	Residents with pressure ulcers (Stage 1-4) on target assessment (M2a >0 OR I3a-e =707.0)
Denominator	All residents with a valid target assessment and not qualifying as high risk.
Exclusions	Exclusions for both measures: Residents satisfying any of the following conditions are excluded from all risk groups (high and low, high, and low) – this is 1, with 1, 2, and 3 below being 1.1, 1.2, and 1.3: 1. The target assessment is an admission (AA8a = 01) assessment. 2. The QM did not trigger (resident is not included in the QM numerator) AND the value of M2a is missing on the target assessment. 3. The resident is in a facility with a Chronic Care Admission Sample size of 0 (i.e., there are no admission assessments with AA8a = 01 in the facility over the previous 12 months). 4. The resident does not qualify as high-risk AND the value of G1a(A) or G1b(A) is missing on the target assessment. 5. The resident does not qualify as high-risk AND the Value of B1 is missing on the target assessment.
Risk Adjustment	None.
Data Source	Standardized clinical instrument
Level	Facility (e.g., hospital, nursing home)
Setting	Nursing home/ Skilled Nursing Facility (SNF)

Measure# 0201: Pressure ulcer prevalence	
Steward	The Joint Commission, California Nursing Outcome Coalition
Description	The total number of patients that have hospital-acquired (nosocomial) stage II or greater pressure ulcers on the day of the prevalence study.
Numerator	<p>Patients surveyed on an eligible reporting unit that have at least one stage II or greater [National Pressure Ulcer Advisory Panel (NPUAP)] hospital-acquired pressure ulcer on the day of the prevalence study. Time Window: Quarterly Prevalence Study Day</p> <p>Eligible reporting units are those units meeting the requirements as defined in the Type of Unit data element and listed in the strata definitions provided under section number 10. See study methodology in item #9 below.</p> <p>Included Populations:</p> <ul style="list-style-type: none"> • Hospital-Acquired Pressure Ulcers – Pressure Ulcers of Stage II or greater AND the ulcer is discovered or documented after the first 24 hours from the time of inpatient admission. <p>Data Elements:</p> <ul style="list-style-type: none"> • Observed Pressure Ulcer • Observed Pressure Ulcer – Hospital-Acquired • Observed Pressure Ulcer – Stage
Denominator	<p>All patients on the selected unit at the time of the study who are surveyed for the study by Type of Unit and overall. Time window: Quarterly Prevalence Study Day</p> <p>The current language "selected units" is not suggesting that hospitals "choose" units for survey. Rather, inherent in prevalence study method is that ALL eligible units are surveyed at the same point in time (note labor, delivery, post partum and psychiatry units are excluded). Hospitals do not choose units to be surveyed; units surveyed are standardized across institutions by those eligible reporting units as defined in the Type of Unit data element and listed in the strata definitions provided under section number 10. The word "selected" will be deleted for clarity.</p> <p>Included Populations: Patients 18 years or older who are admitted to critical care, step-down, medical, surgical and medical-surgical combined units that are surveyed for the study.</p> <p>Data Elements:</p> <ul style="list-style-type: none"> • Admission Date • Birthdate • Sex • Type of Unit • Prevalence Study Date
Exclusions	<p>Excluded Populations:</p> <ul style="list-style-type: none"> • Patients less than 18 years of age • Patients who refuse to be assessed • Patients who are off the unit at the time of the prevalence study, i.e., surgery, x-ray, physical therapy, etc. • Patients who are medically unstable at the time of the study for whom assessment would be contraindicated at the time of the study, i.e., unstable blood pressure, uncontrolled pain, or fracture waiting repair. • Patients who are actively dying and pressure ulcer prevention is no longer a treatment goal.
Risk Adjustment	Stratified by hospital size.
Data Source	Paper Medical Record, Electronic Health/Medical Record, Other
Level	Group of clinicians (facility, dept/unit, group), Facility (e.g., hospital, nursing home)
Setting	Hospital

Measure# 0202: Falls with injury	
Steward	American Nurses Association
Description	All documented patient falls with an injury level of minor (2) or greater.
Numerator	<p>Total number of patient falls of injury level minor or great (whether or not assisted by a staff member) by hospital unit during month x 1000.</p> <p>Included Populations:</p> <ul style="list-style-type: none"> • Falls with Fall Injury Level of 2 “minor” or greater, including assisted and repeat falls with an Injury level of 2 or greater • Patient injury falls occurring while on an eligible reporting unit <p>Excluded Populations:</p> <p>Falls by:</p> <ul style="list-style-type: none"> • Visitors • Students • Staff members • Falls by patients from eligible reporting unit, however patient was not on unit at time of fall (e.g., patients falls in radiology department) • Falls on other unit types (e.g., pediatric, obstetrical, rehab, etc) • Falls with Fall Injury Level of 1 “none” <p>Data Elements: Collected at a patient level</p> <ul style="list-style-type: none"> • Month • Year • Age • Gender • Event Type (fall, assisted fall, or repeat fall) • Fall Injury Level • Type of Unit • Fall Risk Assessment • Fall Risk • Fall Prevention Protocol
Denominator	<p>Denominator Statement: Patient days by Type of Unit during the calendar month.</p> <p>Time Window: Calendar Month</p> <p>Included Populations:</p> <ul style="list-style-type: none"> • Inpatients, short stay patients, observation patients and same day surgery patients who receive care on in-patient units for all or part of a day. • Adult critical care, step-down, medical, surgical, medical-surgical combined units <p>Four (4) Patient Days reporting methods are recognized:</p> <p>Method 1-Midnight Census</p> <p>This is adequate for units that have all in-patient admissions. It is the least accurate method for units that have both in-patient and short stay patients. The daily number should be summed for every day in the month.</p> <p>Method 2-Midnight Census + Patient Days from Actual Hours for Short Stay Patients</p> <p>This is an accurate method for units that have both in-patients and short stay patients. The short stay “days” should be reported separately from midnight census and will be summed to obtain patient days. The total daily hours for short stay patients should be summed for the month and divided by 24.</p> <p>Method 3-Midnight Census + Patient Days from Average Hours for Short Stay Patients</p> <p>This method has been eliminated from the list of acceptable reporting methods.</p> <p>Method 4-Patient Days from Actual Hours</p> <p>This is the most accurate method. An increasing number of facilities have accounting systems that track the actual time spent in the facility by each patient. Sum actual hours for all patients, whether in-patient or short stay, and divide by 24.</p> <p>Method 5-Patient Days from Multiple Census Reports</p> <p>Some facilities collect censuses multiple times per day (e.g., every 4 hours or each shift). This method is more accurate than the Midnight Census, but not as accurate as Midnight Census + Actual Short Stay hours, or as Actual Patient Hours. A sum of the daily average censuses can be calculated to determine patient days for the</p>

	<p>month on the unit.</p> <p>It is recommended that data collectors consistently use the same method for reporting patient days. However, units with short stay patients should transition from Midnight Census to Method 2 or Method 4 when it becomes feasible.</p> <p>Data Elements:</p> <ul style="list-style-type: none"> • Month • Year • Patient Days Reporting method which includes midnight census and short stay patient days • Type of Unit
Exclusions	Excluded Populations: Other unit types (e.g., pediatric, psychiatric, obstetrical, rehab, etc.)
Risk Adjustment	Stratification by facility size and unit; documentation of falls risk assessment on admission; fall protocol implementation; level of patient activity prior to fall
Data Source	Paper Medical Record, Electronic Health/Medical Record, Electronic source - Other, Other
Level	Group of clinicians (facility, dept/unit, group)
Setting	Hospital
Measure# 0203: Restraint prevalence (vest and limb only)	
Steward	The Joint Commission, California Nursing Outcome Coalition
Description	Total number of patients that have vest and/or limb restraint (upper or lower body or both) on the day of the prevalence study.
Numerator	<p>Patients surveyed on the eligible reporting unit that have a vest restraint and/or limb restraint (upper or lower or both) on the day of the prevalence study.</p> <p>Time Window: Quarterly Prevalence Study Day</p> <p>Excluded Populations:</p> <ul style="list-style-type: none"> • Restraints that are only associated with medical, dental, diagnostic, or surgical procedures and is based on standard practice for the procedure (sometimes referred to as "treatment restraints") • seclusion • restraint uses that are forensic or correctional restrictions used for security purposes unrelated to clinical care • devices used to meet the assessed needs of a patient who requires adaptive support or a medical protective device <p>Data Elements:</p> <ul style="list-style-type: none"> • Physical Restraint • Type of Restraint
Denominator	<p>All patients on an eligible reporting unit at the time of the study and are surveyed for the study by Type of Unit.</p> <p>Time Window: Quarterly Prevalence Study Day</p> <p>Eligible reporting units are those units meeting the requirements as defined in the Type of Unit data element and listed in the strata definitions provided below section number 10 Stratification Details.</p> <p>Included Populations: Patients 18 years or older who are admitted to critical care, step-down, medical, surgical and medical-surgical combined units that are surveyed for the study.</p> <p>Data Elements:</p> <ul style="list-style-type: none"> • Admission Date • Birthdate • Prevalence Study Date • Sex • Type of Unit
Exclusions	<p>Excluded Populations:</p> <ul style="list-style-type: none"> • Patients less than 18 years of age • Patients who are off the unit at the time of the prevalence study, i.e. surgery, x-ray, physical therapy, etc.
Risk Adjustment	
Data Source	Paper Medical Record, Electronic Health/Medical Record
Level	Group of clinicians (facility, dept/unit, group), Facility (e.g., hospital, nursing home)
Setting	Hospital

Measure# 0239: Venous Thromboembolism (VTE) Prophylaxis	
Steward	American College of Emergency Physicians, American Medical Association, National Committee for Quality Assurance, American Medical Association - Physician Consortium for Performance Improvement
Description	Percentage of patients aged 18 years and older undergoing procedures for which VTE prophylaxis is indicated in all patients, who had an order for Low Molecular Weight Heparin (LMWH), Low-Dose Unfractionated Heparin (LDUH), adjusted-dose warfarin, fondapar
Numerator	Surgical patients, who had an order for VTE prophylaxis (low molecular weight heparin (LMWH), low-dose unfractionated heparin (LDUH), adjusted-dose warfarin, fondaparinux or mechanical prophylaxis) to be given within 24 hours prior to incision time or within 24 hours after surgery end time.
Denominator	All surgical patients aged 18 years and older undergoing procedures for which VTE prophylaxis is indicated in all patients.
Exclusions	Documentation of medical reason(s) for patient not receiving any accepted form of VTE prophylaxis (LMWH, LDUH, adjusted-dose warfarin, fondaparinux or mechanical prophylaxis) within 24 hours prior to incision time or 24 hours after surgery end time Exclude patients for whom VTE prophylaxis was not ordered by reason of appropriate denominator exclusion. If using electronic data, exclude patients using the following code: Append a modifier (1P) to the CPT Category II code to report patients with documented circumstances that meet the denominator exclusion criteria.
Risk Adjustment	
Data Source	Electronic Claims
Level	Individual clinician (physician, nurse)
Setting	Hospital
Measure# 0263: Patient Burn	
Steward	Ambulatory Surgical Centers Quality Collaborative
Description	Percentage of ASC admissions experiencing a burn prior to discharge
Numerator	Ambulatory surgical center (ASC) admissions experiencing a burn prior to discharge.
Denominator	All ASC admissions.
Exclusions	None
Risk Adjustment	None.
Data Source	Paper Medical Record, Electronic Claims, Other
Level	Individual clinician (physician, nurse)
Setting	Hospital, Ambulatory Surgical Centers
Measure# 0265: Hospital Transfer/Admission	
Steward	Ambulatory Surgical Centers Quality Collaborative
Description	Percentage of ASC admissions requiring a hospital transfer or hospital admission prior to being discharged from the ASC.
Numerator	ASC admissions requiring a hospital transfer or hospital admission prior to being discharged from the ASC.
Denominator	All ASC admissions
Exclusions	None.
Risk Adjustment	
Data Source	Other
Level	Individual clinician (physician, nurse)
Setting	Hospital, Ambulatory Surgical Centers

Measure# 0266: Patient Fall	
Steward	Ambulatory Surgical Centers Quality Collaborative
Description	Percentage of ASC admissions experiencing a fall in the ASC.
Numerator	ASC admissions experiencing a fall in the ASC.
Denominator	All ASC admissions.
Exclusions	ASC admissions experiencing a fall outside the ASC.
Risk Adjustment	None
Data Source	Other
Level	Individual clinician (physician, nurse)
Setting	Hospital, Ambulatory Surgical Centers
Measure# 0267: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant	
Steward	Ambulatory Surgical Centers Quality Collaborative
Description	Percentage of ASC admissions experiencing a wrong site, wrong side, wrong patient, wrong procedure, or wrong implant.
Numerator	ASC admissions experiencing a wrong site, wrong side, wrong patient, wrong procedure, or wrong implant.
Denominator	All ASC admissions.
Exclusions	None
Risk Adjustment	None.
Data Source	Other
Level	Individual clinician (physician, nurse)
Setting	Hospital, Ambulatory Surgical Centers
Measure# 0298: Central Line Bundle Compliance	
Steward	Institute for Healthcare Improvement
Description	Percentage of intensive care patients with central lines for whom all elements of the central line bundle are documented and in place. The central line bundle elements include: <ul style="list-style-type: none"> • Hand hygiene , • Maximal barrier precautions upon insertion • Chlorhex
Numerator	Number of intensive care patients with central lines for whom all elements of the central line bundle are documented and in place. The central line bundle elements include: <ul style="list-style-type: none"> • Hand hygiene , • Maximal barrier precautions upon insertion • Chlorhexidine skin antisepsis • Optimal catheter site selection, with subclavian vein as the preferred site for non-tunneled catheters in patients 18 years and older • Daily review of line necessity with prompt removal of unnecessary lines
Denominator	Total number of intensive care patients with central lines on day of week of sample.
Exclusions	Exclude patients less than 18 years of age at the date of ICU admission and patients outside the intensive care unit and patients whose lines were not placed in the intensive care unit
Risk Adjustment	
Data Source	Paper Medical Record
Level	Facility (e.g., hospital, nursing home)
Setting	Hospital

Measure# 0299: Surgical Site Infection Rate	
Steward	Centers for Disease Control and Prevention, Centers for Medicare & Medicaid Services
Description	Percentage of surgical site infections occurring within thirty days after the operative procedure if no implant is left in place or with one year if an implant is in place in patients who had an NHSN operative procedure performed during a specified time
Numerator	<p>Number of surgical site infections occurring within thirty days after the operative procedure if no implant is left in place or with one year if an implant is in place in patients who had an NHSN operative procedure performed during a specified time period and the infection appears to be related to the operative procedure. Infections are identified on original admission or upon readmission to the facility of original operative procedure within the relevant time frame (30 days for no implants; within 1 year for implants).</p> <p>Two types of CDC-defined SSIs are included:</p> <p>(1) A deep incisional SSI must meet the following criteria:</p> <ul style="list-style-type: none"> • Infection occurs within 30 days after the operative procedure if no implant is left or within one year if implant is in place and the infection appears to be related to the operative procedure and • involves deep soft tissues (e.g., fascial and muscle layers) of the incision and • patient has at least one of the following: <ul style="list-style-type: none"> a) purulent drainage from the deep incision but not from the organ/space component of the surgical site b) a deep incision spontaneously dehisces or is deliberately opened by a surgeon and is culture-positive or not cultured when the patient has at least one of the following signs or symptoms: fever (>38°C), or localized pain or tenderness. A culture-negative finding does not meet this criterion. c) an abscess or other evidence of infection involving the deep incision is found on direct examination, during reoperation, or by histopathologic or radiologic examination d) diagnosis of a deep incisional SSI by a surgeon or attending physician. <p>Note: There are two specific types of deep incisional SSIs:</p> <p>1) Deep Incisional Primary (DIP) - a deep incisional SSI that is identified in a primary incision in a patient that has had an operation with one or more incisions (e.g., C-section incision or chest incision for CABG)</p> <p>2) Deep Incisional Secondary (DIS) - a deep incisional SSI that is identified in the secondary incision in a patient that has had an operation with more than one incision (e.g., donor site [leg] incision for CBGB)</p> <p>(2) An organ/space SSI must meet the following criteria:</p> <ul style="list-style-type: none"> • Infection occurs within 30 days after the operative procedure if no implant is left or within one year if implant is in place and the infection appears to be related to the operative procedure and • infection involves any part of the body, excluding the skin incision, fascia, or muscle layers, that is opened or manipulated during the operative procedure and • patient has at least one of the following: <ul style="list-style-type: none"> a). purulent drainage from a drain that is placed through a stab wound into the organ/space b). organisms isolated from an aseptically obtained culture of fluid or tissue in the organ/space c). an abscess or other evidence of infection involving the organ/space that is found on direct examination, during reoperation, or by histopathologic or radiologic examination d) diagnosis of an organ/space SSI by a surgeon or attending physician. <p>Specific sites of an organ/space SSI may be identified¹¹</p>
Denominator	<p>Number of NHSN operative procedures performed during a specified time period stratified by:</p> <ul style="list-style-type: none"> • Type of NHSN operative procedure and • NNIS SSI risk index: <p>Every patient having the selected procedure is assigned one (1) risk point for each of the following three factors:</p> <ul style="list-style-type: none"> o Surgical wound classification = clean contaminated or dirty

	<ul style="list-style-type: none"> o American Society of Anesthesiologists (ASA) preoperative severity of illness score = 3, 4, or 5 o Duration of operation >t hours, where t varies by type of NHSN operative procedure and is the approximate 75th percentile of the duration of the procedure rounded to the nearest whole number of hours. <p>Note: For operative procedures performed using lapyroscopes and endoscopes the use of a lapyroscope is an additional factor that modifies the risk index.</p>
Exclusions	Exclude Procedures Not Included Under The Definition Of NHSN Operative Procedure And Excludes Superficial SSI.
Risk Adjustment	
Data Source	Paper Medical Record
Level	Facility (e.g., hospital, nursing home)
Setting	Hospital
Measure# 0301: Surgery patients with appropriate hair removal	
Steward	The Joint Commission
Description	Percentage of surgery patients with surgical hair site removal with clippers or depilatory or no surgical site hair removal
Numerator	Surgery patients with surgical hair site removal with clippers or depilatory or no surgical site hair removal
Denominator	All selected surgery patients Include patients with an ICD-9-CM Principal Procedure code or ICD-9-CM Other Procedure Codes of selected surgeries.
Exclusions	Exclude the following patients: <ul style="list-style-type: none"> • less than 18 years of age; • performed their own hair removal; and • patients whose mode of hair removal could not be determined.
Risk Adjustment	
Data Source	Paper Medical Record, Electronic Claims
Level	Facility (e.g., hospital, nursing home)
Setting	Hospital

Measure# 0302: Ventilator Bundle	
Steward	Institute for Healthcare Improvement
Description	Percentage of intensive care unit patients on mechanical ventilation at time of survey for whom all four elements of the ventilator bundle are documented and in place. The ventilator bundle elements are: <ul style="list-style-type: none"> • Head of bed (HOB) elevation 30 degrees or great
Numerator	Number of intensive care unit patients on mechanical ventilation at time of survey for whom all four elements of the ventilator bundle are documented and in place. The ventilator bundle elements are: <ul style="list-style-type: none"> • Head of bed (HOB) elevation 30 degrees or greater (unless medically contraindicated); noted on 2 different shifts within a 24 hour period • Daily “sedation interruption” and daily assessment of readiness to extubate; process includes interrupting sedation until patient follow commands and patient is assessed for discontinuation of mechanical ventilation; Parameters of discontinuation include: resolution of reason for intubation; inspired oxygen content roughly 40%; assessment of patients ability to defend airway after extubation due to heavy sedation; minute ventilation less than equal to 15 liters/minute; and respiratory rate/ tidal volume less than or equal to 105/min/L(RR/TV< 105) • SUD (peptic ulcer disease) prophylaxis • DVT (deep venous thrombosis) prophylaxis
Denominator	Total number of intensive care unit patients on mechanical ventilation.
Exclusions	Patients less than 18 years of age at the date of ICU admission.
Risk Adjustment	
Data Source	Paper Medical Record
Level	Facility (e.g., hospital, nursing home)
Setting	Hospital
Measure# 0337: Decubitus Ulcer (PDI 2)	
Steward	Agency for Healthcare Research and Quality
Description	Percent of surgical and medical discharges under 18 years with ICD-9-CM code for decubitus ulcer in secondary diagnosis field.
Numerator	All discharges, age under 18 years, with International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes denoting decubitus ulcer in any secondary diagnosis field
Denominator	All surgical and medical discharges age under 18 years defined by specific Surgical and Medical Diagnosis Related Group (DRG), include only patients with a length of stay of 5 or more days
Exclusions	Exclude patients with an ICD-9-CM code of decubitus ulcer in the principal diagnosis field; with an ICD-9-CM procedure code for debridement or pedicle graft before or on the same day as a major operating room procedure (surgical cases only); with an ICD-9-CM procedure code for debridement or pedicle graft as the only major operating room procedure (surgical cases only); Major Diagnostic Category (MDC) 9 (Skin, Subcutaneous Tissue, and Breast) or MDC 14 (Pregnancy, Childbirth and the Puerperium); newborns less than 500 grams; Neonates (age < 28 days) and patients transferring in from long term care facility (ASOURCE =3) or an acute care facility (ASOURCE = 2)
Risk Adjustment	
Data Source	Electronic Claims
Level	Facility (e.g., hospital, nursing home)
Setting	Hospital

Measure# 0345: Accidental Puncture or Laceration (PSI 15)	
Steward	Agency for Healthcare Research and Quality
Description	Percent of medical and surgical discharges, 18 years and older, with ICD-9-CM code denoting accidental cut, puncture, perforation, or laceration in any secondary diagnosis field.
Numerator	Medical and surgical discharges with ICD-9-CM code denoting accidental cut, puncture, perforation, or laceration in any secondary diagnosis field.
Denominator	Discharges, age 18 years and older, defined by specific DRGs
Exclusions	<ul style="list-style-type: none"> • with ICD-9-CM code denoting technical difficulty (e.g., accidental cut, puncture, perforation, or laceration) in the principal diagnosis field or secondary diagnosis present on admission, if known • MDC 14 (pregnancy, childbirth, and puerperium). • with ICD-9-CM code for spine surgery
Risk Adjustment	<p>The predicted value for each case is computed using a hierarchical model (logistic regression with hospital random effect) and covariates for gender, age (in 5-year age groups), modified CMS DRG, and the AHRQ Comorbidity category. The reference population used in the regression is the universe of discharges for states that participate in the HCUP State Inpatient Data (SID) for the years 2002-2004 (combined), a database consisting of 37 states and approximately 90 million discharges. The expected rate is computed as the sum of the predicted value for each case divided by the number of cases for the unit of analysis of interest (i.e., hospital, state, and region). The risk adjusted rate is computed using indirect standardization as the observed rate divided by the expected rate, multiplied by the reference population rate.</p> <p>Required data elements: CMS Diagnosis Related Group (DRG); CMS Major Diagnostic Category (MDC); patient gender; age in years at admission; International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) principal and secondary diagnosis codes.</p>
Data Source	Electronic Claims
Level	Facility (e.g., hospital, nursing home)
Setting	Hospital
Measure# 0346: Iatrogenic Pneumothorax (PSI 6) (risk adjusted)	
Steward	Agency for Healthcare Research and Quality
Description	Percent of medical and surgical discharges, 18 years and older, with ICD-9-CM code of iatrogenic pneumothorax in any secondary diagnosis field.
Numerator	Discharges with ICD-9-CM code of iatrogenic pneumothorax in any secondary diagnosis field
Denominator	Discharges, age 18 years and older, defined by specific surgical and medical DRGs
Exclusions	Patients in MDC 14 (pregnancy, childbirth and puerperium); with principal diagnosis (ICD-9-CM) code of iatrogenic pneumothorax (secondary diagnosis field if present on admission); with an ICD-9-CM diagnosis code of chest trauma or pleural effusion; with an ICD-9-CM procedure code of diaphragmatic surgery; and with an ICD-9-CM procedure code indicating thoracic surgery, lung or pleural biopsy, or assigned to cardiac surgery DRGs
Risk Adjustment	<p>The predicted value for each case is computed using a hierarchical model (logistic regression with hospital random effect) and covariates for gender, age (in 5-year age groups), modified CMS DRG, and the AHRQ Comorbidity category. The reference population used in the regression is the universe of discharges for states that participate in the HCUP State Inpatient Data (SID) for the years 2002-2004 (combined), a database consisting of 37 states and approximately 90 million discharges. The expected rate is computed as the sum of the predicted value for each case divided by the number of cases for the unit of analysis of interest (i.e., hospital, state, and region). The risk adjusted rate is computed using indirect standardization as the observed rate divided by the expected rate, multiplied by the reference population rate.</p> <p>Required data elements: CMS Diagnosis Related Group (DRG); CMS Major Diagnostic Category (MDC); patient gender; age in years at admission; International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) principal and secondary diagnosis codes.</p>
Data Source	Electronic Claims
Level	Facility (e.g., hospital, nursing home)
Setting	Hospital

Measure# 0347: Death in Low Mortality DRGs (PSI 2)	
Steward	Agency for Healthcare Research and Quality
Description	Percent of in-hospital deaths, age 18 years and older, in DRGs with less than 0.5% mortality rate.
Numerator	Number of in-hospital deaths
Denominator	Discharges, age 18 years and older, in DRGs with less than 0.5% mortality rate. If a DRG is divided into "without/with complications," both DRGs must qualify as low mortality for inclusion
Exclusions	Patients with any ICD-9-CM code for trauma, immunocompromised state or cancer
Risk Adjustment	None.
Data Source	Electronic Claims
Level	Facility (e.g., hospital, nursing home)
Setting	Hospital
Measure# 0348: Iatrogenic Pneumothorax in Non-Neonates (PDI 5) (risk adjusted)	
Steward	Agency for Healthcare Research and Quality
Description	Percent of medical and surgical discharges, age under 18 years, with ICD-9-CM code of iatrogenic pneumothorax in any secondary diagnosis field.
Numerator	Discharges with ICD-9-CM code of iatrogenic pneumothorax in any secondary diagnosis field
Denominator	Discharges, age under 18 years, defined by specific surgical and medical DRGs
Exclusions	Neonates (birth weight less than 2500 grams); patients with an ICD-9-CM code of iatrogenic pneumothorax in neonates in the principal diagnosis field (secondary diagnosis field if present on admission); with an ICD-9-CM code of thoracic surgery, lung or pleural biopsy or diaphragmatic surgery repair or assigned to a cardiac surgery DRG; with a diagnosis code of chest trauma or pleural effusion; MDC of 14 (pregnancy, childbirth, puerperium) normal newborn and newborns less than 500 grams
Risk Adjustment	<p>The predicted value for each case is computed using a hierarchical model (logistic regression with hospital random effect) and covariates for gender, birthweight (500g groups), age in days (29-60, 61-90, 91+), age in years (in 5-year age groups), modified CMS DRG and AHRQ CCS comorbidities. The reference population used in the regression is the universe of discharges for states that participate in the HCUP State Inpatient Data (SID) for the years 2002-2004 (combined), a database consisting of 37 states and approximately 20 million pediatric discharges. The expected rate is computed as the sum of the predicted value for each case divided by the number of cases for the unit of analysis of interest (i.e., hospital, state, and region). The risk adjusted rate is computed using indirect standardization as the observed rate divided by the expected rate, multiplied by the reference population rate.</p> <p>Required data elements: CMS Diagnosis Related Group (DRG); CMS Major Diagnostic Category (MDC); age in days up to 364, then age years at admission; International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) principal and secondary diagnosis codes.</p>
Data Source	Electronic Claims
Level	Facility (e.g., hospital, nursing home)
Setting	Hospital

Measure# 0349: Transfusion Reaction (PSI 16)	
Steward	Agency for Healthcare Research and Quality
Description	Percent of medical and surgical discharges, 18 years and older, with ICD-9-CM code for transfusion reaction in any secondary diagnosis field.
Numerator	Discharges with an ICD-9-CM code for transfusion reaction in any secondary diagnosis field
Denominator	Discharges, age 18 years and older, defined by specific surgical and medical DRGs
Exclusions	Patients with an ICD-9-CM code for transfusion reaction in the principal diagnosis field (secondary diagnosis field if present on admission)
Risk Adjustment	None.
Data Source	Electronic Claims
Level	Facility (e.g., hospital, nursing home)
Setting	Hospital
Measure# 0350: Transfusion Reaction (PDI 13)	
Steward	Agency for Healthcare Research and Quality
Description	Percent of medical and surgical discharges, under 18 years of age, with an ICD-9-CM code for transfusion reaction in any secondary diagnosis field.
Numerator	Discharges with an ICD-9-CM code for transfusion reaction in any secondary diagnosis field
Denominator	Discharges, age under 18 years, defined by specific surgical and medical DRGs
Exclusions	Patients with MDC 14 (pregnancy, childbirth, puerperium); with an ICD-9-CM code for transfusion reaction in the principal diagnosis field (secondary diagnosis field if present on admission); and neonates less than 500 grams
Risk Adjustment	
Data Source	Electronic Claims
Level	Facility (e.g., hospital, nursing home)
Setting	Hospital

Measure# 0352: Failure to Rescue In-Hospital Mortality (risk adjusted)	
Steward	Children's Hospital of Philadelphia
Description	Percentage of patients who died with a complications in the hospital.
Numerator	<p>Patients who died with a complication plus patients who died without documented complications. Death is defined as death in the hospital.</p> <p>All patients in an FTR analysis have developed a complication (by definition).</p> <p>Complicated patient has at least one of the complications defined in Appendix B. Complications are defined using the secondary ICD9 diagnosis and procedure codes and the DRG code of the current admission.</p> <p>Comorbidities are defined in Appendix C using secondary ICD9 diagnosis codes of the current admission and primary or secondary ICD9 diagnosis codes of previous admission within 90 days of the admission date of the current admission.</p> <p>*When physician part B is available, the definition of complications and comorbidities are augmented to include CPT codes.</p>
Denominator	<p>General Surgery, Orthopedic and Vascular patients in specific DRGs with complications plus patients who died in the hospital without complications.</p> <p>Inclusions: adult patients admitted for one of the procedures in the General Surgery, Orthopedic or Vascular DRGs (see appendix A)</p>
Exclusions	Patients over age 90, under age 18.
Risk Adjustment	<p>Risk Adjustment: Model was developed using logistic regression analysis.</p> <p>Associated data elements: age in years, sex, race, comorbidities, DRGs (combined with and without complications) and procedure codes within DRGs, transfer status.</p> <p>Failure to rescue is adjusted using a logistic regression model where y is a failure and the total N is composed of patients who develop a complication and patients who died without a complication.</p> <p>According to developer: The model adjustment variables can vary. We have found that FTR results are fairly stable, even with little adjustment, since all patients in an FTR analysis have developed a complication (by definition), they are a more homogenous group of patients than the entire population. Hence severity adjustment plays somewhat less of a role than in other outcome measures.</p>
Data Source	Electronic Claims
Level	Facility (e.g., hospital, nursing home)
Setting	Hospital

Measure# 0353: Failure to Rescue 30-Day Mortality (risk adjusted)	
Steward	Children's Hospital of Philadelphia
Description	Percentage of patients who died with a complication within 30 days from admission.
Numerator	<p>Patients who died with a complication plus patients who died without documented complications. Death is defined as death within 30 days from admission.</p> <p>Complicated patient has at least one of the complications defined in Appendix B. Complications are defined using the secondary ICD9 diagnosis and procedure codes and the DRG code of the current admission.</p> <p>Comorbidities are defined in Appendix C using secondary ICD9 diagnosis codes of the current admission and primary or secondary ICD9 diagnosis codes of previous admission within 90 days of the admission date of the current admission.</p> <p>*When physician part B is available, the definition of complications and comorbidities are augmented to include CPT codes.</p>
Denominator	<p>General Surgery, Orthopedic and Vascular patients in specific DRGs with complications plus patients who died without complications within 30 days of admission.</p> <p>Inclusions: adult patients admitted for one of the procedures in the General Surgery, Orthopedic or Vascular DRGs (see appendix A)</p>
Exclusions	Patients over age 90, under age 18.
Risk Adjustment	<p>Risk Adjustment: Model was developed using logistic regression analysis.</p> <p>Associated data elements: age in years, sex, race, comorbidities, DRGs (combined with and without complications) and procedure codes within DRGs, transfer status.</p> <p>Failure to rescue is adjusted using a logistic regression model where y is a failure and the total N is composed of patients who develop a complication and patients who died without a complication.</p> <p>According to developer: The model adjustment variables can vary. We have found that FTR results are fairly stable, even with little adjustment, since all patients in an FTR analysis have developed a complication (by definition), they are a more homogenous group of patients than the entire population. Hence severity adjustment plays somewhat less of a role than in other outcome measures.</p>
Data Source	Electronic Claims
Level	Facility (e.g., hospital, nursing home)
Setting	Hospital
Measure# 0362: Foreign Body left after procedure (PDI 3)	
Steward	Agency for Healthcare Research and Quality
Description	Discharges with foreign body accidentally left in during procedure per 1,000 discharges
Numerator	All discharges, age under 18 years, with International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for foreign body left in during a procedure in any secondary diagnosis field
Denominator	All surgical and medical discharges age under 18 years defined by specific Surgical and Medical Diagnosis Related Group (DRG)
Exclusions	Exclude patients with an ICD-9-CM code of foreign body left in during a procedure in the principal diagnosis field, Major Diagnostic Category (MDC) 14 (Pregnancy, Childbirth and the Puerperium), newborns less than 500 grams and neonates (age < 28 days)
Risk Adjustment	None.
Data Source	Electronic Claims
Level	Facility (e.g., hospital, nursing home)
Setting	Hospital

Measure# 0363: Foreign Body Left in During Procedure (PSI 5)	
Steward	Agency for Healthcare Research and Quality
Description	Discharges with foreign body accidentally left in during procedure per 1,000 discharges
Numerator	Number of discharges, age 18 years and older, with an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code for foreign body in any secondary diagnosis field
Denominator	All surgical and medical discharges age 18 years and older defined by specific Surgical and Medical Diagnosis Related Group (DRG) Include patients in MDC 14
Exclusions	Exclude patients with principal diagnosis (ICD-9-CM) code of foreign body
Risk Adjustment	None.
Data Source	Electronic Claims
Level	Facility (e.g., hospital, nursing home)
Setting	Hospital
Measure# 0371: Venous Thromboembolism (VTE) Prophylaxis	
Steward	The Joint Commission
Description	This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after hospital admission or surgery end date for surgeries that start the day of or the day after hosp
Numerator	Patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given: ? the day of or the day after hospital admission ? the day of or the day after surgery end date for surgeries that start the day of or the day after hospital admission
Denominator	All patients Inclusions: Not applicable
Exclusions	Patients: ? Patients less than 18 years of age ? Patients who have a length of stay (LOS) < two days and > 120 days ? Patients with Comfort Measures Only documented ? Patients enrolled in clinical trials ? Patients who are direct admits to intensive care unit (ICU), or transferred to ICU the day of or the day after hospital admission with ICU LOS = one day ? Patients with ICD-9-CM Principal Diagnosis Code of Mental Disorders or Stroke as defined in Appendix A, Table 7.01, 8.1 or 8.2 ? Patients with ICD-9-CM Principal or Other Diagnosis Codes of Obstetrics or VTE as defined in Appendix A, Table 7.02, 7.03 or 7.04 ? Patients with ICD-9-CM Principal Procedure Code of Surgical Care Improvement Project (SCIP) VTE selected surgeries as defined in Appendix A, Tables 5.17, 5.19, 5.20, 5.21, 5.22, 5.23, 5.24
Risk Adjustment	
Data Source	Paper Medical Record, Electronic Claims, Electronic Health/Medical Record
Level	Facility (e.g., hospital, nursing home)
Setting	Hospital

Measure# 0589: Rheumatoid Arthritis New DMARD Baseline Serum Creatinine	
Steward	Resolution Health, Inc.
Description	This measure identifies adult patients with a diagnosis of rheumatoid arthritis who received appropriate baseline serum creatinine testing within 90 days before to 14 days after the new start of methotrexate, leflunomide, azathioprine, D-Penicillamine, i
Numerator	Patients in the denominator who received serum creatinine testing within 90 days before to 14 days after the new start of methotrexate, leflunomide, azathioprine, D-Penicillamine, intramuscular gold, cyclosporine, or cyclophosphamide during the measurement year.
Denominator	Patients >=18 years old with a history of rheumatoid arthritis and a new start of methotrexate, leflunomide, azathioprine, D-Penicillamine, intramuscular gold, cyclosporine, or cyclophosphamide anytime from the beginning of the measurement year to 14 days prior to the end of the measurement year. (This list of DMARDs will hereafter be referred to as 'DMARD needing baseline SCR')
Exclusions	The measure excludes patients who have had an inpatient hospitalization during the measurement year because UB04 claims do not document individual lab tests ordered during an inpatient stay.
Risk Adjustment	no
Data Source	Electronic Claims, Electronic Pharmacy Data, Other
Level	Individual clinician (physician, nurse), Community/Population, Health Plan, Group of clinicians (facility, dept/unit, group), Integrated delivery system
Setting	Ambulatory Care (office/clinic), Community Healthcare, Health Plan